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SUMMARY 
 
 
 
The detonation of a radiological dispersion device (RDD) may result in a situation where 
many individuals are exposed to contamination due to the inhalation of radioactive materials. 
Assessments of contamination may need to be performed by emergency response personnel in 
order to triage a potentially exposed public. The feasibility of using readily available standard 
2x2-inch sodium-iodide [NaI(Tl)] detectors to determine the internal contamination level of a 
patient following the acute inhalation of a radionuclide has been investigated.  
An assessment of the level of contamination after a selected period of time requires 
computer modeling, since the inhalation and distribution of nuclides cannot readily be modeled 
in the laboratory. The 2x2-NaI(Tl) detector response was simulated using MCNP-5 [1], and the 
model was validated via a series of experimental benchmark measurements using a polymethyl 
methacrylate (PMMA) slab phantom. Upon collecting experimental data using PMMA 
thicknesses ranging from 0-mm to 90-mm in 6-mm increments, the measurements were 
simulated using MCNP. The detector response was calculated for six radionuclides to ensure that 
the detector model was validated over a broad range of gamma-ray energies. The integrated 
photopeaks in the benchmark measurements were compared with the corresponding MCNP 
model. From these comparisons, scaling factors were calculated for each nuclide. The purpose of 
simulating multiple thicknesses was to verify that each nuclide scaling factor was constant 
regardless of chest-wall thickness, thus showing no variance in detector response. Such 
validation is essential in reproducing the actual detector response for extended geometries and 
sources. 
 
xi 
 
Upon verification of the detector model, six anthropomorphic phantoms (Reference Male, 
Reference Female, Adipose Male, Adipose Female, Post-Menopausal Adipose Female, and 
Child) based on the MIRD-V (Medical Internal Radiation Dose) phantoms [2] were used to 
model nuclides distributed to simulate inhaled contamination. The nuclides assessed with the 
anthropomorphic phantoms included 241Am, 60Co, 137Cs, 131I, and 192Ir. The modeling assumed 
that all external contamination had already been removed and that only one radionuclide was 
inhaled and has been identified. The detectors were placed at four positions on the phantoms: 
anterior right torso, posterior right torso, anterior neck, and lateral left thigh. The detected count-
rate varied with respect to detector position and the resulting optimal detector location was 
determined on the body. The simulation data were used with biokinetic modeling data to 
determine time-dependent count-rate values for each radionuclide. Threshold limits were 
determined for use in triaging, based on an intake that would lead to a minimum committed 
effective dose of 250-mSv [3]. The source distribution and activity in the body as a function of 
post-inhalation time was determined using the Dose and Risk Calculation software (DCAL) [4]. 
The detector response was determined as a function of count-rate per becquerel of 
activity at initial intake. This was converted to a count-rate value per 250-mSv of intake for 
triage use by first responders. A set of procedure sheets for use by first responders was compiled 
for each of the phantoms and nuclides investigated. These procedure sheets were designed to 
instruct first responders in detector use, determination of background, acquisition of patient data, 
and the use of count-rate decision levels to determine if further medical attention is required. 
Although readily available, the 2x2-NaI(Tl) requires initial set-up and calibration by a skilled 
technician before use by first responders with limited experience in radiation detection 
instrumentation. 
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CHAPTER 1:  INTRODUCTION 
 
 
 
 The attacks of September 11, 2001 have stirred the nation to strengthen its homeland 
security defenses and have reaffirmed the need to refine emergency preparedness in the purview 
of an imminent terrorist threat using weapons of mass destruction (WMD). Although a “nuclear 
9/11” or an attack using a fission-based weapon are of paramount concern, the concerns 
regarding WMDs have also extended to include radiological terrorism. A radiological dispersion 
device (RDD), colloquially referred to as a “dirty bomb”, is a radiological weapon that employs 
conventional explosives with radioactive material with the purpose of dispersing radioactive 
material and consequently contaminating a large area or population with the possibility of 
causing severe radiation induced-illnesses to its victims. The use of an RDD is not just limited to 
the use of explosive means to disperse radioactive material, but can also disperse radiological 
contamination passively using aerosolized material. The use of such a weapon by extremists 
would cause ubiquitous psychological and economic detriment.  
 To date, there has been only one confirmed case of radiological terrorism, occurring in 
Moscow in November 1995 by radical Chechen separatists [5]. Although the decision to detonate 
the 137Cs-dynamite device was abandoned, the capability of such radical groups to commit acts 
of radiological terrorism was revealed to be tangible and imminent. Although an RDD event has 
fortunately been eluded, the effects of the radiological accident in Goiânia, Brazil in 1987, 
involving a stolen medical device containing 137Cs, highlight the shared detrimental 
consequences of such an event [5].  
 Radiological contamination can occur in the form of alpha, beta, or gamma radiation. A 
joint report by the Department of Energy (DOE) and Nuclear Regulatory Commission (NRC) 
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identified 241Am, 60Co, 137Cs, and 192Ir as radionuclides that pose the highest risk in the 
employment of an RDD [6]. Such nuclides are available industrially as medical diagnostic 
devices and in smoke detectors (241Am), food irradiators (60Co), and medical radiation therapy 
devices for cancer treatment (137Cs, 192Ir). In addition to these four nuclides, 131I was investigated 
at the request of the Centers for Disease Control and Prevention, as it is commonly used in the 
medical diagnosis of thyroid cancer.  
 In light of such threats, a risk reduction strategy to mitigate the effects in the event of an 
RDD, including the development of emergency response plans and training for first responders, 
has become a priority concern for security-minded officials. An RDD event would leave its 
victims both externally and internally contaminated. Methods for assessing external 
contamination are better defined; however, methods for assaying internal contamination for mass 
populations are still deficient, especially in a case where substantial amounts of radioactive 
material have been inhaled or ingested, and internalized. Although whole-body counters are the 
preferred method of assessing contamination (as opposed to invasive bioassay procedures), their 
use in a triage scenario are obviated by their limited availability, and consequently their limited 
abilities in handling screening mass populations for internalized contamination. Whole-body 
counters are additionally too sensitive for the assaying required in an emergency triage scenario. 
Such limitations are the inherent motivation to investigate whether readily available handheld 
instruments could be used by first responders to assess the inhaled dose in a triage environment. 
Sodium-iodide detectors are available in most university and radiation safety laboratories in 
major metropolitan cities. These detectors are spectrometers, capable of producing a spectrum 
with photopeaks characteristics of a given radionuclide. They are robust compared to their 
semiconductor counterparts, and are comparatively inexpensive to purchase. Such detectors 
3 
consequently possess the characteristics of a portable detector that may be useful in a triage 
scenario in assessing the internalized contamination of RDD victims. 
4 
CHAPTER 2:  BACKGROUND  
 
 
 
 The five radionuclides investigated were those said by the DOE/NRC study to be the 
nuclides of “greatest concern” in the deployment of an RDD [6]. Both organizations have 
published numerous reports on emergency response, medical, and triage procedures to be 
followed in the event of a deployment of an RDD. The Department of Homeland Security 
Working Group on RDD Preparedness has established a report on the medical treatment of 
radiological casualties [7]. In this study, in-vitro medical triage procedures were recommend for 
assessing internal dose by employing nasal swabs - which were said to represent 5% of the 
deposition in the lungs - in addition to cytogenetic biodosimetry and complete blood counts.  
 In-vivo methods are preferable to in-vitro methods, as they facilitate the rapid screening 
of triage patients without cumbersome and invasive procedures that are time consuming, limited 
in resources, and highly subject to error. In the latter category, whole body counters are the 
preferred method of assessing internal and external contamination.  With over 300 people 
requiring assay, whole-body counters were successfully employed in assessing contamination in 
the 137Cs accident in Goiânia, Brazil [8]. In this situation, a whole-body counter employing a 20-
cm NaI(Tl) detector was installed at 2.05-m above the center of the room, and was collimated 
and shielded with 5-cm of lead. The detector was installed at a standoff distance due to the high 
level of contaminant activity in the subjects. Studies by Kramer et al. have investigated the use 
commercially available portal monitors (Constellation Technology Corporation P3 and Canberra 
Industries MiniSentry) for emergency response [9], in addition to assessing the feasibility of 
whole body counting by employing a commercially available portable instrument (ORTEC 
5 
Detective) involving a HPGe detector for automated nuclide identification and spectral analysis, 
and a compensated Geiger-Mueller tube to determine dose-rate [10].  
 A common obstacle in performing counts externally over the lungs includes 
compensating for varying chest wall thicknesses. Kramer et al. have studied the uncertainty 
introduced by varying chest thicknesses using the Lawrence Livermore National Laboratory 
torso phantom and a lung counting system employing an array of four large area germanium 
detectors [11]. In addition, Kramer et al. found that the variation in the chest wall thickness 
depth profile for male workers varies between 13% and 26%, contributing an uncertainty factor 
of approximately 1.07 [12]. In this study, they additionally postulate that the uncertainty factor 
for females is higher, around 1.2 of under- or over-estimation. 
 However, in addition to portal monitor applications, the use of NaI(Tl) detectors has been 
limited to the use of medical instrumentation such as gamma cameras and thyroid uptake systems 
[13], [14], [15]. These thyroid uptake systems employ NaI(Tl) detectors as spectrometers, but are 
attached via a lead collimator, typically 6-inches in length, and possess an automated data 
acquisition system. In order to validate the detector models to account for varying chest-wall 
thicknesses, Angistein et al. conducted simulations using acrylic slab phantoms and water 
phantoms with a thyroid uptake probe to compensate for varying chest-wall thicknesses. This 
study consequently determined that waste monitoring, gamma camera, and thyroid uptake 
systems were all capable of potential use following an RDD event [13]. 
 Assaying inhaled contamination to determine the committed effective dose using 
handheld and readily available radiation detectors has been the focus of recent work at the 
Georgia Institute of Technology. Investigating the use of the aforementioned thyroid uptake 
systems have been conducted by Lorio [14], then later by Scarboro [15], for assaying the 
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committed effective dose due to inhaled contamination. Lorio’s investigation using the Atomlab 
950 Thyroid Uptake System additionally assessed the feasibility of using such a system to 
estimate dose in the event of a radiological attack and incorporated a validated Monte Carlo 
model to estimate counts due to lung uptake. Although Lorio’s work was able to ascertain the 
use of this system following a radiological attack, Scarboro’s work with the Capintec Captus 
3000 thyroid uptake probe incorporated biokinetics to determine the time-dependent movement 
of inhaled radionuclide contaminants throughout the body, and also calculated the retention 
fraction by select organs over time. Scarboro’s work additionally employed a set of decision 
levels for assaying inhaled dose for use in a first-responder triage scenario.  
 Although commercially available NaI(Tl) systems are available and have been proven 
effective for use in radiological emergency response, these detectors tend to be automated, 
costly, and lack the customizability due to their task-specific design. Portal monitors and whole 
body counters are too sensitive and are limited in availability for emergency triage scenarios. 
Medical assay equipment would only be available in hospitals in extremely limited quantities. 
Therefore, this study investigates the use of a standard 2x2-NaI(Tl)  - a spectrometer in its bare 
form - in a triage field scenario to assess the committed effective dose of a patient due to inhaled 
contamination. 
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CHAPTER 3:  METHODOLOGY 
 
 
 
In order to assess the triage criteria for the inhalation and distribution of nuclides over a 
select period of time, computer modeling was employed since the inhalation and distribution of 
nuclides cannot feasibly be reproduced in the laboratory. Thus, a 2x2-NaI(Tl) detector was 
modeled for Monte Carlo simulation and validated via a series of benchmark measurements, as 
outlined in the depiction of the procedural overview in Figure 3.0.1. This detector model was 
validated by conducting experimental measurements using a polymethyl methacrylate (PMMA) 
slab phantom and six gamma-ray sources spanning a broad range of energies. Validation of the 
model resulted from the comparison of the experimental data from the slab phantoms to its 
simulated Monte Carlo model. Upon verification of the Monte Carlo detector model, six 
anthropomorphic phantoms - representative of various body types - were modeled with nuclides 
distributed throughout select organs for each of the five sources under consideration.  After 
simulation, the data were incorporated with the time-dependent biokinetic modeling, from which 
the threshold count-rate values determined whether a subject is considered to have received a 
significant dose as per pre-established guidelines. 
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Figure 3.0.1 Procedure for Determining Inhalation Contamination Triage Levels Using a 
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3.1 Canberra 802-2x2 NaI(Tl) Detector 
 
 
 
 The 802-2x2 NaI(Tl) detector assembly is manufactured by Canberra Inc. [16] and 
contains a 2 Ø×2-inch thallium-activated sodium-iodide crystal manufactured by Saint Gobain 
Crystals [17]. The 802-2x2 NaI(Tl) detector is shown in Figure 3.1.1. The detector assembly 
includes the 2x2-inch NaI(Tl) crystal, a photomultiplier tube, and an internal magnetic/light 
shield, which are all hermetically sealed in an aluminum housing. The rear of the detector 
contains a 14-pin connector, capable of mounting a Canberra Model 2007P combination tube 
base and pre-amplifier. The detector works in conjunction with external high voltage and 
amplifier modules to produce an output spectrum via a multi-channel analyzer (MCA).  The 
detector-module circuit for data acquisition with the sodium-iodide detector is shown in Figure 
3.1.2 and depicts the mounted tube base and pre-amplifier assembly. Data were acquired using 
the Canberra 2007P combination tube base and preamplifier, which was powered by a Canberra 
3002D High Voltage Power Supply at 0.91 kV and amplified by the Canberra 2022 module with 
coarse gain ×300, fine gain ×0.613, 0.5µs shaping time, and UNIPOLAR output to the MCA. 
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Figure 3.1.1 Canberra 802-2x2 NaI(Tl) Detector 
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Figure 3.1.2 2x2 NaI(Tl) Detector Circuit Set-up 
 
 
 
Canberra’s Multiport II MCA, a module extra to the 802-2x2 detector assembly, is 
expandable to 16,384 channels and employs the Genie 2000 Gamma Acquisition and Analysis 
Software [18] as a user interface. A spectrum collected using this software is shown in Figure 
3.1.3. In this experiment, 1024 MCA channels were used over the energy range investigated. 
Using more channels would subject the spectrometer to a higher counting error per acquisition 
channel. Using the MCA software and known gamma-ray radionuclide sources, the sodium-
iodide detector was  manually energy calibrated. It was best to select gamma-ray sources that 
cover a full range of energies to ensure accurate calibration. The MCA software is capable of 
storing customized energy calibration files, thus enabling the spectrometer to be calibrated with 
various gamma-ray sources and to be saved/recalled for later use by the same detector at specific 
module settings.  
11 
The MCA is also capable of selecting regions of interest (ROI) over a specified channel 
or energy range, and provides the number of counts in that region for a given live acquisition 
time from which a count rate can be easily calculated. For data saved in 1024 channels, the first 
two channels contain the real and live acquisition times and the remaining 1022 channels store 
data as counts per channel. These features are not unique to the Canberra Multiport II or 802-2x2 
detector, but are representative of MCA software tools that are readily available to operate in 
conjunction with sodium-iodide detectors. 
 
 
 
 
Figure 3.1.3 Canberra Genie 2000 Gamma Acquisition and Analysis Software User Interface  
  
 
 
In this experiment, the MCA interface was calibrated using known checked sources to a 
gain of 3.18-keV per channel commencing from the first channel containing energy information 
(channel 3) to channel 1024. Thus, energy information is stored in 1022 channels and was fit 
linearly to known photopeaks to yield the energy calibration given Figure 3.1.4.  
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Figure 3.1.4 Energy Calibration Curve for 2x2 Na(Tl) Detector  
 
 
 
 Based on the source calibration data, the ROIs were selected to encompass the photopeaks of the 
radionuclides studied. The MCA is able to store ROIs, but does not consistently or accurately 
automatically select the peak ROIs, thus necessitating manual assignment over the peak area. 
Although the MCA is capable of manually assigning and storing ROIs, this must be done for 
specific detector and module settings for a given energy calibration. This therefore necessitates 
that the detector be operated at the settings at which it was energy calibrated. The ROIs can 
thence be assigned as the user requires, making the detector system very customizable, and 
capable of saving/recalling data for analysis ex-post facto.  
Energy (keV) = 3.18*(Channel-2) – 2.3  
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3.2 Polymethyl Methacrylate Slab Phantom Measurements 
 
 
 
The computational model of the 802-2X2  NaI(Tl) detector was validated via a series of 
benchmark measurements using a PMMA slab phantom. As depicted in Figure 3.2.1, the slab 
phantom consisted of varying thicknesses of PMMA, followed by a source holder to affix the 
radionuclide source, and Virtual WaterTM [19] behind the source. For all benchmark 
measurements, a 100-mm thickness of Virtual Water was maintained behind the source holder to 
simulate the gamma-ray backscattering that would result from human tissue. The source holder 
was constructed from a 6mm-thick sheet of PMMA bored with a cylindrical hole to center and 
encapsulate the radionuclide source, preventing it from shifting during data acquisition and 
maintaining the source position at the center of the detector face. 
 The six sources investigated with the PMMA slab include 241Am, 133Ba, 60Co, 137Cs, 
54Mn, and 22Na. These nuclides were selected for their broad range of gamma energies 
interacting with the detector. Additionally, 241Am, 60Co, and 137Cs, have been identified as 
materials of greatest concern in the employment of an RDD [6]. The energies and intensities for 
the primary photopeaks under analysis for the nuclides employed in the PMMA benchmark 
measurements were obtained from the Oak Ridge National Laboratory program, RadToolbox 
[20], and are summarized in Table 3.2.1.  
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Figure 3.2.1 PMMA Slab Phantom Set-up 
 
 
 
 Table 3.2.1 Photopeak Gamma Energies Investigated for Slab Phantom 
Radionuclide Sources  
 
Nuclide Peak Energy  
(keV) 
Intensity 
241Am 59.5 0.357 
133Ba 276.397 0.071 
302.851 0.184 
356.005 0.622 
60Co 1173.2 0.998 
1332.5 0.999 
137Cs 661.7 0.898 
54Mn 834.8 0.999 
22Na 511.0 
(Annihilation Peak) 
1.798 
1274.5 0.999 
 
Virtual  
Water 
 
Source 
Holder 
 
       PMMA   
 
2x2 
NaI(Tl) 
Detector 
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Varying thicknesses of PMMA were placed in front of the source holder, ranging in 6-
mm increments from 0-mm to 90-mm between the source and detector (with the exception of 
241Am and 133Ba measurements, for which data were taken up to only 60-mm in thickness). 
PMMA was chosen for its tissue-like attenuation behavior with gamma-rays; thus, varying 
thicknesses of PMMA were used to mimic varying chest-wall thicknesses in humans. Increasing 
the PMMA thickness, and thus the source-to-detector distance, adds an additional inverse of 
distance-squared factor to the attenuation behavior of PMMA on the incident gamma-rays.  
The acquisition time was determined based on the number of counts accumulated under 
the ROI encompassing the selected photopeaks. This was set to acquire until at least 10,000 
gross counts (prior to background subtraction) were accumulated – corresponding to 
approximately 1% counting error under the peak. The ROIs for the investigated nuclides, listed 
in Table 3.2.1, were selected to encompass the peak(s) under investigation and were based on the 
detector response to bare sources (without the PMMA phantom). These ROIs were determined 
during energy calibration with the bare sources and were applied as the integral counting regions 
for the PMMA phantoms. The ROIs over which the counts were integrated for each radionuclide 
were selected to capture the nuclide’s primary photopeaks. For example, if a radionuclide 
emitted three distinct, high-intensity gamma-ray lines, then three separate ROIs were applied, 
each encompassing a corresponding photopeak. In practice, the endpoints of the ROIs were set 
manually, such that they encompassed the edges of the photopeaks to be counted. A sample ROI 
selection for both the experimental and MCNP simulated peaks for the 0.662-MeV peak for 
137Cs is shown in Figure 3.2.2. 
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Figure 3.2.2 Sample Region of Interest Comparison for 137Cs for Experimental Slab 
Phantom Data and MCNP Simulation Model 
 
 
 
As listed in Table 3.2.1, the ROIs for 133Ba and 60Co consisted of the amalgamation of 
multiple adjacent photopeaks. These peaks were merged into a single ROI due to their close 
proximity to each other, thus preserving count rates, as well as reducing the error required to 
separate the peaks due to variable detector resolution. The remaining nuclides’ ROIs were singly 
selected peak regions, since these characteristic photopeaks were relatively isolated in energy 
vis-à-vis other emissions and were high intensity emissions. The selection of the ROI was 
manually conducted, as the boundaries encompassing the photopeaks selected were specific to 
this detector. Other 2x2 NaI(Tl) detectors will differ in detector resolution and will thus require 
that the ROIs be manually selected to encompass the photopeaks. In addition, the peak area was 
determined by subtracting the continuum under the peak of the ROI caused by a superimposed 
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continuum, using a linear interpolation between the peak boundaries to estimate the continuum 
counts to be subtracted. This approach is well known and outlined by Knoll [21], and yields 
sufficient accuracy for this data analysis. 
Summation peak events were also taken into consideration when acquiring data using the 
PMMA slab phantoms. When two or more gamma-rays are coincidently incident on the detector, 
a count is recorded in the pulse-height spectrum at a value equal to the sum of the two coincident 
gamma-rays [21]. This is common for a nuclide that emits multiple gammas during its decay. 
These events are not a separate gamma-ray in a nuclide’s decay scheme, but the coincident 
detection of two (or more) true gamma-rays. If enough of these events occur, then a sum 
coincidence peak is observed in the spectrum centered about an energy equal to the sum of the 
two incident gamma-rays. Summations can occur for two full energy gamma-rays or between 
Compton scattered gamma-rays coincident with a full energy gamma-ray. This is purely a 
property of the incident event rate, detector size and response, and does not occur in 
computational modeling. Thus, for each single count in the sum coincidence peak, these counts 
must be redistributed back to the contributing peaks to attempt to preserve the true number of 
integral counts in the ROI.  
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3.3 MCNP Detector Model Validation 
 
 
 
Benchmark measurements were used to validate the computational detector model by 
comparing the experimental measurements taken using the PMMA slab phantom for the six 
gamma-ray sources with its simulated Monte Carlo model. The detector was modeled using Los 
Alamos N-Particle Transport Code MCNP-5 [1]. The detector model response was simulated at 
each incremental thickness of PMMA, thus replicating the slab phantom benchmark 
experiments. Consequently, the detector response was determined for each of the six isotopes 
employed in the benchmark measurements to ensure that the detector model was validated over a 
broad range of gamma-ray energies. The integrated pulse-height region for each ROI in the 
benchmark measurements were compared with the respective Monte Carlo slab phantom model, 
from which a detector response efficiency (scaling) factor was calculated for each nuclide over 
all PMMA thicknesses. Consequently, validation of the computational detector model is essential 
in reproducing an accurate detector response.  
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3.4 Anthropomorphic MIRD Phantoms and Biokinetics 
 
 
 
 The Medical Internal Radiation Dose (MIRD)-based anthropomorphic phantoms [2] and 
a child phantom (constructed using BodyBuilder [22]) were employed as the computational 
human models into which radionuclides were distributed to represent inhaled contamination.  
The MIRD phantoms are based on the Reference Male and Female body types, and are based on 
the mathematical phantoms initially developed at Oak Ridge National Laboratory [2]. The 
MCNP-coded versions of the Reference Male and Female used in this work were originally 
created at Pacific Northwest National Laboratory, based on the MIRD phantoms [23] and the 
ICRP 23 recommendations [24]. The development of the adipose phantoms by Simpkins and 
Hertel was an extension of these models [25], and resulted in three adult phantoms: Adipose 
Male, Adipose Female, and Post-Menopausal Adipose Female. These phantoms have been 
modified recently at the Georgia Institute of Technology by Burns, with the addition of a 2-mm 
layer of skin tissue to the phantoms [26]. Thus, a total of six phantoms - five adult (two 
reference, three adipose) and an androgynous 10-year old child phantom - were simulated.  
The count-rates due to inhaled radionuclides distributed biokinetically in the body were 
simulated using MCNP anthropomorphic phantom models. The MCNP detector model, after 
validation by the slab phantom benchmark experiment, was used to simulate the detector 
response at various locations on the surface of the anthropomorphic phantoms. The validated 
detector model was placed in various locations about the phantom, with an objective of 
identifying which detector location would yield optimal counts per unit inhaled dose of nuclide. 
Four locations were selected for study: anterior neck, anterior and posterior right upper 
torso, and lateral left thigh. All four locations were employed using the Reference Male 
20 
phantom, though the anterior upper-right torso position was omitted from the remainder of the 
phantoms due to adipose/breast tissue attenuation at this location with the Reference Female, 
Adipose Male, Adipose Female and Post-Menopausal Adipose Female phantoms. With a 
validated detector model strategically placed about these phantoms, the detector response due to 
inhaled contamination was derived.  
 Each of the phantoms was simulated with inhaled contamination for five radionuclides, 
listed in Table 3.4.1. These sources (241Am, 60Co, 137Cs, 131I, 192Ir) were selected as the nuclides 
of “greatest concern” in the employment of an RDD [6]. With a computational ROI analysis 
similar to that of the aforementioned slab phantom, the energies and intensities for primary 
photopeaks under analysis for the nuclides employed in the anthropomorphic phantoms were 
RadToolbox [20] and are summarized in Table 3.4.1.  
 
Table 3.4.1 Photopeak Gamma Energies Investigated for Anthropomorphic Phantom 
Radionuclide Sources  
 
Nuclide Peak Energy  
(keV) 
Intensity 
241Am 59.537 0.357 
60Co 1173.237 0.998 
1332.501 0.999 
137Cs 661.657 0.898 
131I 364.480 0.812 
192Ir 316.500 0.829 
 
 
 
 The radioactive source distribution in the body as a function of post-inhalation time was 
determined using the Dose and Risk Calculation software (DCAL) [4], a code developed at Oak 
Ridge National Laboratory by Eckerman et al. The DCAL software implements the ICRP 
Publication 66 respiratory biokinetics to determine the retention factors for a given radionuclide 
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inhalation class in the body as a function of time [27]. As will be discussed the next section, the 
data from DCAL can be used in conjunction with the MCNP count-rates from the contaminated 
MIRD phantoms to determine the detector count-rate due to inhaled contamination for each 
radionuclide after a given post-inhalation time. 
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3.5 Triage Clinical Decision Levels and Protocols 
 
 
 
 Simulations were performed for the anthropomorphic phantoms with appropriately 
distributed radionuclide contamination as a function of bodily retention per unit time. The count-
rate per unit activity inhaled was determined to ascertain the count-rate corresponding to the 
action/screening-level dose. These data will be used as criteria for determining whether further 
medical attention is required. The threshold action screening level for triage activity used in this 
phase of the work was set to a committed effective dose of 250-mSv [3]. 
From the four detector positions modeled, the detector location yielding the highest 
count-rate per 250-mSv intake for each nuclide was selected for screening. A procedure sheet 
was developed for each phantom-radionuclide pairing to instruct first responders in use of the 
detector for triaging, as well as how to determine count-rate decision levels for various time 
periods following the initial inhalation during the radiological event. 
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CHAPTER 4:  COMPUTATIONAL MODELS 
 
 
 
 The basis of assessing inhaled contamination relies on computer simulation of the 
detector response for the inhaled contamination distributed in the body as a function of time.  All 
photon transport calculations were simulated using MCNP-5 [1]. A summary of the 
computational models to simulate the detector response for both the PMMA slab phantoms and 
the MIRD phantoms is presented in this chapter. 
 
 
 
4.1 2x2 NaI(Tl) Detector Model 
 
 
 
 In order to ensure an accurate detector response, the 802-2x2 NaI(Tl) detector was 
modeled in detail.  A pulse-height tally (MCNP F8) was performed over the active region of the 
detector crystal to determine the pulse-height spectrum.  Since actual measurements were 
accumulated as 1022-channel pulse-height spectra, the MCNP pulse-height spectra were 
similarly binned and tallied into 1022 channels spanning a total energy range of 3.248-MeV in 
3.18-keV increments per channel (refer to §3.1). The dimensions and physical characteristics of 
the detector are outlined in the sample MCNP input file in Appendix A and the detector material 
properties are presented in Table 4.1.1. A VisEd [28] rendering of the detector model is given in 
Figure 4.1.1. 
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Table 4.1.1 Detector Material Specifications 
Detector Component Weight Percent 
Composition 
Thickness 
(cm) 
Density 
(g/cm3) 
Detector casing [16]  100.00% Al 0.20 2.94 
Aluminum-oxide 
powder coating [29] 
52.93% Al 
47.07% O 
0.16 0.55 
Compressed  
foam [30],[31] 
14.37% H 
85.63% C 
0.19 0.93 
Saint Gobain  
NaI(Tl) Crystal [17] 
15.33% Na 
84.67% I 
5.08×5.08 3.667 
Photomultiplier 
Tube Low Density 
Glass [32], [31] 
53.26% O 
46.74% Si 
0.30 0.94 
 
 
 
 
            
Figure 4.1.1 VisEd Representation of Canberra Model 802-2x2 NaI(Tl) Detector 
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4.2 Slab Phantom Model 
 
 
 
An MCNP model of the PMMA slab phantom for each source was constructed. A point 
source was defined to simulate each of the gamma-ray sources, and a pulse-height tally was 
performed over the active volume of the detector crystal to simulate the pulse height spectra for 
each radionuclide. A separate slab phantom model was constructed for each PMMA thickness – 
from 0-mm to 90-mm (with the aforementioned exception of 241Am and 133Ba, taken to 60-mm). 
The material characteristics of the slab phantom are summarized in Table 4.2.1 and a sample 
detector and slab MCNP input file is given in Appendix A. 
 
 
 
Table 4.2.1 Slab Phantom Material Specifications 
Slab Phantom 
Component 
Weight Percent 
Composition  
Thickness 
(cm) 
Density 
(g/cm3) 
PMMA Slabs &  
Source Holder [14] 
8.06% H 
59.99% C 
31.95% O 
0.6 
(increments) 
1.19 
Virtual Water [19] 0.64% H 
63.99% C 
2.53% N 
25.14% O 
0.39% Cl 
7.31% Ca 
 
10 
 
1.03 
Polyester Source [15] 8.06% H 
60.02% C 
31.92% O 
0.4 Ø 1.00 
Surrounding Air [32] 75.58% N 
23.14% O 
1.28% Ar 
n/a 0.001293 
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A VisEd [28] representation of the slab model with the detector is depicted in Figures 4.2.1 and 
4.2.2, while the source collision interactions are portrayed in Figure 4.2.3, where the dots 
represent collisions by the source particles. 
 
 
 
 
Figure 4.2.1 VisEd Representation of PMMA Slab Phantom Model 
 
 
 
Figure 4.2.2 3-D VisEd Representation of PMMA Slab Phantom Model 
Source Holder 
Source 
 
PMMA Slabs 
2x2 NaI(Tl)  
Detector 
Virtual Water 
 
 
Air 
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Figure 4.2.3 VisEd Representation of Source Particle Collision Interactions with Detector 
 
 
 
The scaling factors for all PMMA thicknesses were determined for each radionuclide. 
The scaling factors are the ratios of the simulated MCNP count rates with the detector counts in 
the relevant peak ROIs of the benchmark measurements. The purpose of simulating multiple 
PMMA thicknesses for each nuclide was to verify that the detector scaling factor was relatively 
constant regardless of PMMA thicknesses; that is, it did not vary with thickness. This 
consequently validates the detector model for each radionuclide regardless of source-detector 
geometry. The average ratio for each radionuclide was used as a detector-reading scaling factor 
applicable to other source-detector geometries. 
The energies and intensities for the nuclides employed in the source definitions in the 
PMMA simulations were obtained from RadToolbox [20] and are summarized in Table 4.2.1.  
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Table 4.2.1 Slab Phantom Source Gamma Energy-Intensity Data 
241Am 133Ba 60Co 22Na 
Energy 
(keV) 
Emission 
Intensity 
Energy 
(keV) 
Emission 
Intensity 
Energy 
(keV) 
Emission 
Intensity 
Energy 
(keV) 
Emission 
Intensity 
13.760 0.025 30.625 0.341 1173.237 0.9985 511 1.798 
 13.944 0.219 30.973 0.631 1332.501  0.9998 1274.54 
 
0.999 
16.835 0.058 34.987 0.122 
17.061 0.022 80.997 0.338 137Cs 54Mn 
17.750 0.188 276.397 0.071 
Energy 
(keV) 
Emission 
Intensity 
Energy 
(keV) 
Emission 
Intensity 
17.992 0.020 302.851 0.184  
661.657 
 
0.898 
 
834.848 
 
0.99976 20.785 0.046 356.005 0.622 
26.345 0.024 383.851 0.089 
59.537 0.357 30.625 0.341 
 
 
 
Since the MCNP tallies are normalized to emissions per source particle, the tally output 
was multiplied by the exact source activity of the sources employed in the benchmark 
measurements and branching ratios in order to replicate laboratory measurements. The branching 
ratio is the number of particles emitted per decay, where four isotopes (241Am, 133Ba, 60Co, 22Na) 
emit multiple gamma rays for each particle decay. Therefore, the sum of the branching ratios for 
each of the radionuclides must be considered. The assay activities of the sources employed in the 
benchmark measurements and the summed branching ratios for the ROIs are summarized in 
Table 4.2.2. 
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Table 4.2.2 Source Assay Activity 
 
Isotope Assay 
Date 
Initial 
Activity 
(µCi) 
Half- 
Life  
(y) 
Experiment 
Activity 
(µCi) 
Measurement 
Date 
(MM/DD/YY) 
Branching 
Ratio 
241Am 12/09/05 7.50 432 7.48 12/10/07 0.9592  
133Ba 12/09/05 5.20 10.7 6.53 01/11/08 2.3966  
60Co 12/09/05 5.10 5.27 4.02 
 
09/29/07 0.8528  
137Cs 12/09/05 4.90 30.0 4.70 
 
09/30/07 1.9988  
54Mn 12/09/05 5.00 0.86 1.15 
 
10/03/07 0.9997  
22Na 12/09/05 5.00 2.60 3.09 09/29/07 2.7974  
 
 
 
In the unsmoothed MCNP pulse-height tally, all photoelectric interactions result in a 
delta function at the photon energy rather than a resolution-broadened photopeak. Thus, the 
Gaussian Energy Broadening function [1] in MCNP was used to simulate the detector resolution, 
based on the full-width-at-half-maximum (FWHM) data, though exact resolution matching is 
very time consuming. In principle, the use of the unsmoothed counts at the full gamma-ray 
energy would also accomplish the same purpose, as would smoothing to the monoenergetic 
output using alternative software. The parameters required for the GEB function (a, b, and c) 
were calculated based on the measured detector response, and iteratively fit [33] to Equation 
4.2.1 to obtain the GEB parameters.  
 
2FWHM a b E cE= + +
   [Equation 4.2.1] 
 In this expression, 
E = Energy (MeV) 
  FWHM =full-width-at-half-maximum value of photopeak (MeV) 
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  The detector resolution calculated from the benchmark measurements for each of the six 
radionuclides is plot in Figure 4.2.3 with the computational resolution using the GEB fit 
parameters.  The parameters and usage of the GEB function may be found in the example MCNP 
input file in Appendix A, as well as in Figure 4.2.3. According to the Canberra 802-2x2 NaI(Tl) 
detector specifications, the crystal has a peak resolution of 8.5% for the 0.662-MeV 137Cs peak 
[16], where the detector employed in the benchmark data collection had a peak resolution of 
7.46%, and the corresponding GEB fit had resolution of 7.31%. 
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Figure 4.2.3 Detector Resolution and Simulated Resolution using GEB Fit Parameters 
 
 
To illustrate the effect of the GEB smoothing function, a measured spectrum, an unsmoothed 
(raw) MCNP tally, and a GEB smoothed MCNP tally are compared in Figure 4.2.4 for 137Cs.   
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Figure 4.2.4 Comparison of Measured Spectrum for 137Cs with 30-mm PMMA with 
Corresponding Smoothed and Unsmoothed MCNP Simulated Spectra  
 
 
 
As outlined in detail in §3.2, the corresponding integral count rates for the primary 
photopeaks for each nuclide used in the benchmark measurements were similarly used for the 
computational simulations. Yet, unlike the experimental data, computational data did not 
simulate sum-coincidence effects, as shown in Figure 4.2.5. Since summation effects are a 
property of the detector and incident count-rate, it is not necessary to simulate this effect 
computationally. In each case, the count-rate due to photoelectric depositions can be determined, 
whether they are manifested in the ROI photopeak or summation peak. The ROIs employed to 
determine the integral count rates from the MCNP PMMA slab phantoms are summarized for 
each nuclide in Table 4.2.3. 
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Figure 4.2.5 Comparison of Measured Spectrum for 60Co with Summation Peak for 30-mm 
PMMA with Corresponding Smoothed MCNP Simulated Spectrum 
 
 
 
Table 4.2.3 MCNP Slab Phantom Counting Regions of Interest 
Nuclide Peak Energy (keV) MCNP Slab Phantom   
ROI (keV) 
241Am 59.5 [35.8, 77.1] 
133Ba 276.4, 356.0 [239.1, 401.1] 
60Co 1173.2, 1332.5 [1099.8, 1414.3] 
 
137Cs 661.7 [582.1, 725.0] 
 
54Mn 834.8 [772.7, 896.6] 
 
22Na 511.0 
 
[451.9, 563.1] 
 1274.5 
 
[1179.2, 1376.2] 
 
   1.17-MeV Peak 
                  1.33-MeV Peak 
 
 
 
 
 
         
 
 
 
2.50-MeV  
Summation Peak 
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The results of the slab phantom benchmark measurements, in combination with the 
computational models of the slab phantoms, are given as energy-dependent scaling factors. 
These results are discussed in §5.1. 
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4.3 MIRD Phantom Models 
 
 
 
Upon verification of the detector model using the slab phantoms, Monte Carlo methods 
were employed to simulate the detector response of the 802-2x2 NaI(Tl) detector to inhaled 
radionuclide contamination. Six anthropomorphic phantoms were contaminated with five 
radionuclides identified likely to be employed in an RDD. To determine the position for 
obtaining an optimal count, the detector was placed at four positions of the body.  An MCNP 
model of each of the anthropomorphic phantoms was constructed with unit sources defined in 
key organs to simulate inhaled contamination. Like the slab phantom computational model, a 
pulse-height tally (F8) was performed over the active volume of the detector crystal to simulate 
the pulse-height spectra for each radionuclide and the same GEB function was used to mimic 
detector resolution properties. A sample MCNP input file of anthropomorphic phantom model 
with the detector placed at each of the four locations is given in Appendix B. 
 
 
 
4.3.1 Anthropomorphic Phantom Characteristics 
 
 
 
These phantoms can be characterized according to their height, body mass, and the 
adipose tissue mass. The Body Mass Index (BMI) is a useful metric in assessing human body 
sizes for adults over age 17 [34]. The BMI is calculated by dividing the mass (kg) by the square 
of the height (m), where a larger BMI is indicative of obesity. The characteristics of each human 
phantom are given in Table 4.3.1 [25]. 
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Table 4.3.1.1 Anthropomorphic Phantom Physical Characteristics  
Phantom Height 
(cm) 
Mass (kg) Adipose Tissue 
Mass (kg) 
BMI 
Reference Male 179 
 
73.1 11 23 
Reference Female 
 
168 56.5 15 20 
Adipose Male 
 
179 93.7 22 30 
Adipose Female 
 
168 73.9 15 26 
Post-Menopausal 
Adipose Female 
168 85.9 27 30 
10-year Androgynous 
Child 
140 32.7 n/a n/a 
 
 
 
4.3.2 Anthropomorphic Phantom Source Contaminant Distribution  
 
 
 
A uniformly distributed source for each of the five isotopes was generated in key organs 
to which the radionuclides would migrate.  The organs selected were based on the ICRP model 
for inhaled dose [4]. The compartments containing sources for each of the five radionuclides are 
summarized in Table 4.3.2.1. Organs also varied slightly between male and female phantoms, 
where male left and right testes were replaced in the female with left and right ovaries, in 
addition to tissue added at the breasts. In comparison to the reference phantoms, the three 
adipose phantoms included additional subcutaneous adipose tissue, as well as adipose tissue 
additions to the abdomen and thighs.  
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The energies and intensities for the nuclides employed in the source definitions in the 
anthropomorphic phantoms were obtained from RadToolbox [20] and are summarized in Table 
4.3.3.2.  
 
 
 
Table 4.3.2.1 Compartments of Interest for each Anthropomorphic Contaminant Nuclide  
Nuclide 
241Am 60Co 137Cs 131I 192Ir Compartments  
of Interest 
Blood X X X X X 
Body Tissue X X X X X 
Cortical Bone X     
Kidneys X    X 
Liver X X   X 
Lower Large Intestines 
Contents X X X X X 
Lungs X X X X X 
Red Marrow X     
Small Intestines Contents X X X X X 
Spleen 
    X 
Stomach Contents X X X X X 
Testes/Ovaries X     
Trabecular Bone X     
Thyroid 
  X   
Upper Large Intestine 
Contents X X X X X 
Urinary Bladder Contents X X X X X 
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 Table 4.3.3.2 Anthropomorphic Phantom Source Gamma Energy-Intensity Data 
241Am 192Ir 131I 
Energy 
(keV) 
Emission 
Intensity 
Energy 
(keV) 
Emission 
Intensity 
Energy 
(keV) 
Emission 
Intensity 
13.760 0.025 9.442 0.015 29.458 0.014 
13.944 0.219 11.071 0.013 29.779 0.026 
16.835 0.058 62.999 0.022 80.183 0.026 
17.061 0.022 65.122 0.027 284.298 0.061 
17.505 0.013 66.831 0.046 364.480 0.812 
17.750 0.188 61.486 0.013 636.973 0.0723 
17.992 0.020 205.791 0.033 722.893 0.018 
20.785 0.046 295.951 0.289 60Co 26.345 0.024 308.447 0.297 
59.537 0.357 316.500 0.829 Energy 
(keV) 
Emission 
Intensity 137Cs 468.060 0.478 484.565 0.031 1173.237 0.9985 
Energy 
(keV) 
Emission 
Intensity 
588.573 0.045 
604.391 0.082 1332.501 0.9998 
661.657 0.898 612.451 0.053 
 
 
 
In the MCNP model, a source-contribution tally modifier (SCX) [1] was implemented in 
conjunction with the pulse-height tally to determine the source organ contribution for each 
source particle that reaches the detector. This value yields the detection efficiency for a unit 
volume source in each organ. The output of the SCX-modified pulse height tally is given as a 
count-rate per becquerel (Bq). The ROIs selected to give the tally count-rate are listed in Table 
4.3.3.3. Three of the radionuclides correspond with the slab phantom measurements and models, 
but the methodology for ROI selection (encompassing the photopeak) was common to all five 
radionuclides. 
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Table 4.3.3.3 MCNP Anthropomorphic Phantom Counting Regions of Interest 
Nuclide MCNP Anthropomorphic Phantom   
ROI (keV) 
241Am [35.8, 77.1] 
60Co [1099.8, 1414.3]  
137Cs [578.9, 721.8] 
131I [315.3, 432.8] 
192Ir [239.1, 394.7] 
 
 
 
4.3.3 Detector Placement on Anthropomorphic Phantoms 
 
 
 
 The count-rates at four detector locations were simulated and the optimal count-rate 
location for each of the five radionuclides was chosen for use in triaging. The torso locations 
over the right lung locations were selected because they resulted in the highest count-rate per Bq 
inhaled. Additionally, the three-lobed right lung is larger than the two-lobed left                    
lung. Posterior and anterior locations were selected due to attenuation affects of breast tissue and 
fat. The neck was selected since 131I is a well known thyroid-seeker. Finally, the thigh location 
was selected, as it represents a large and fleshy muscular region where body tissue seeking 
nuclides may migrate. A VisEd [28] representation of these detector placement locations is 
displayed in Figure 4.3.3.1. 
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Figure 4.3.3.1 Detector Placement Locations on Anthropomorphic Phantom: (A) Anterior 
and Posterior Right Upper Torso; (B) Anterior Neck; and (C) Lateral Left Thigh 
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4.4 DCAL Biokinetic Modeling 
 
 
 
Biokinetic modeling is employed to determine the biological movement of a radionuclide 
through the human body as a function of time. Certain nuclides characteristically accumulate in 
specific organs based on their metabolism in the body. The DCAL [4] software was used to 
determine the accumulated amount of radionuclide present in an organ after a given time – thus 
tracking the biological/metabolic and radiological decay effects. The activity calculation module, 
ACTACAL, is a component in the DCAL package that calculates the time-dependent activity in 
various body compartments for a given parent radionuclide. The DCAL software libraries 
include the ICRP-66 respiratory tract kinetics [27], ICRP-30 gastrointestinal (GI) model [35], 
ICRP-67 urinary bladder voiding model [36], and ICRP-68 GI absorption fractions and system 
biokinetics [37]. Radionuclide data, including energies and intensities from the ICRP-30 
publication data, are employed in DCAL [35]. 
For each of the five radionuclides under investigation (241Am, 60Co, 137Cs, 131I, 192Ir), 
DCAL was executing using ICRP default inhalation classes [38]. For each nuclide run with 
DCAL, inhalation from an environmental source (vis-à-vis an occupational source) was specified 
as the intake pathway. A default of 1-micrometer was used as the particle’s activity mean 
aerodynamic diameter (AMAD) [4]. The lung absorption type (slow [S], moderate [M], fast [F]) 
corresponded to the speed with which the particulate nuclide is absorbed in the lungs [4]. The 
inhalation classes corresponded to ICRP 72 recommended defaults [38]. The default lung 
absorption type for 137Cs and 131I is fast, whereas 60Co and 241Am have a moderate speed uptake. 
Since a default lung absorption type was not specified for 192Ir, a moderate uptake was assumed 
[15]. A summary of the default inhalation classes is displayed in Table 4.4.1. Additionally, 
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summarized in this table are the Environmental Inhalation Dose Coefficients for an adult and 
child. The dose coefficients were obtained from RadToolbox [20], which employs the ICRP 72 
values [38]. Inhalation dose coefficients are reported in units of Bq/rem. For the purposes of 
satisfying the action level criteria of 250-mSv, the dose coefficients can converted to units of Bq 
per 250-mSv of intake. For each of the five radionuclides, the dose coefficients for an adult and 
child are also summarized in Table 4.3.1. 
 
 
  
Table 4.3.1 Environmental Inhalation Dose Coefficients 
Nuclide Default 
Lung 
Absorption 
Type 
Adult Inhalation 
Coefficient  
(Bq/250-mSv 
Intake) 
Child Inhalation 
Coefficient 
 (Bq/250-mSv 
Intake) 
241Am  M 5.95E+03 6.25E+03 
60Co M 2.50E+07 1.67E+07 
137Cs  F 5.43E+07 1.25E+08 
131I F 3.38E+07 1.32E+07 
192Ir  M 4.81E+07 3.29E+07 
 
 
 
The fraction of retention for only the significantly contributing compartments was 
determined for each of the five radionuclides under investigation over a period of 30 days. Note 
that the ET1 (anterior nose) and ET2 (posterior nasal passage, mouth, larynx, pharynx) 
compartments from the ICRP Publication 66 respiratory tract model [27] were subtracted from 
the retained lung fraction calculated in DCAL. This rationale is based on the premise that should 
a patient blow their nose prior to screening, most of the contamination from these passages will 
be removed.  
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The retention is a function of the biological metabolic processes, as well as the nuclide’s 
half-life. The DCAL results are displayed in Figures 4.4.1 through 4.4.6. Sample DCAL results 
for 137Cs (Fast) and 60Co (Moderate) with the ET1 and ET2 compartments removed are displayed 
in Figures 4.4.7 and 4.4.8. 
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Figure 4.4.1 Retention of 241Am (Moderate) in Major Contributing Compartments over a 
30-Day Period 
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Figure 4.4.2 Retention of 60Co (Moderate) in Major Contributing Compartments over a 30-
Day Period 
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Figure 4.4.3 Retention of 137Cs (Fast) in Major Contributing Compartments over a 30-Day 
Period 
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Figure 4.4.4 I Retention of 131I (Fast) in Major Contributing Compartments over a 30-Day 
Period 
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Figure 4.4.5 Retention of 192Ir (Moderate) in Major Contributing Compartments over a 30-
Day Period 
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Figure 4.4.6 Comparison of Total Fraction Retention per Bq Inhaled for each Radionuclide 
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Figure 4.4.7 Comparison of Fraction Retention per Bq for Lung Compartments with ET1 
and ET2 Removed for 137Cs (F) 
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Figure 4.4.8 Comparison of Fraction Retention per Bq for Lung Compartments with ET1 
and ET2 Removed for 60Co (M) 
 
 
 
The DCAL results indicate that a majority of the inhaled contamination is exhaled and 
the remainder travels through the GI and pulmonary systems.  From the five radionuclides, 137Cs 
has the highest retention rate over the 30-day span, where 131I decays more rapidly with the 
lowest retention rate, fastest metabolic uptake, and short half-life. The organs that retain the 
greatest fraction for each nuclide were listed in Table 4.3.2.1. Certain nuclides tend to 
accumulate in specific compartments, as is the case seen with 131I accumulating in the thyroid 
gland. In the case of 137Cs, a significant majority of the contamination is retained in the body 
tissue, which includes breast, adipose, and muscle tissue.  
The understanding of biological and radiological interactions is integral in determining 
dose due to inhaled contamination. Summing the contributions from each source organ from the 
MCNP pulse height tally, in conjunction with the biokinetic modeling - which contributes the 
fractional organ contribution as a function of time per Bq of intake - yields a total count rate 
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from detector per Bq of intake. With the 250-mSv threshold action level for triage screening, the 
final count rates are thus reported in counts-per-minute per 250-mSv intake. This can be easily 
reverted to counts-per-minute per Bq of intake should the action level be modified. 
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CHAPTER 5:  RESULTS 
 
 
 
5.1 Benchmark Experimental and Computational Spectra 
 
 
 
The basis of assessing inhaled contamination in a model of the human body relies on 
computer simulation of the detector response to the time-dependent movement of inhaled 
contamination. In order to ensure an accurate detector response, the benchmark measurements 
were made using a PMMA slab phantom and compared to its MCNP counterpart, thus validating 
the NaI(Tl) detector model. For each of the six radionuclides outlined in Table 3.2.1, a 
comparison of the measured and MCNP simulated spectra for 0-mm, 30-mm, and 60-mm 
attenuating thicknesses of PMMA is presented in Figures 5.1.1 through 5.1.6. 
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Figure 5.1.1 Measured (Solid) and Simulated (Dashed) Spectra for 241Am with  
0-mm, 30-mm, and 60-mm PMMA Attenuation 
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Figure 5.1.2 Measured (Solid) and Simulated (Dashed) Spectra for 133Ba with  
0-mm, 30-mm, and 60-mm PMMA Attenuation 
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Figure 5.1.3 Measured (Solid) and Simulated (Dashed) Spectra for 60Co with  
0-mm, 30-mm, and 60-mm PMMA Attenuation 
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Figure 5.1.4 Measured (Solid) and Simulated (Dashed) Spectra for 137Cs with  
0-mm, 30-mm, and 60-mm PMMA Attenuation 
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Figure 5.1.5 Measured (Solid) and Simulated (Dashed) Spectra 54Mn with  
0-mm, 30-mm, and 60-mm PMMA Attenuation 
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Figure 5.1.6 Measured (Solid) and Simulated (Dashed) Spectra for 22Na with  
0-mm, 30-mm, and 60-mm PMMA Attenuation 
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Summation effects occur in the slab phantom spectra with 137Cs and 60Co. Thus, in order 
to project the actual counts that occur within the primary peak, the fraction of counts in the peak 
ROI was plot as a function of the total counts (including the summation events) and empirically 
fit to a simple-fit function (Figure 5.1.7). Since MCNP does not produce summation events, the 
count-rates from anthropomorphic phantoms must be translatable back into an accurate detector 
response – including summation events.  As disussed in the next section, count rates beyond the 
upper limit of the measured data will tend to indicate noticable summation has occurred. This 
empirical method is further reinforced by requring the traige personnel operating the detector to 
note if the dead-time of the detector is above a certain limit, indicating a high event rate. This 
procedure is outlined in the triage summary sheets in Appendix D, which are used to determine if 
a patient requires further medical attention.  
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Figure 5.1.7 Fraction of Counts Occurring in Region of Interest (ROI) as a Function of 
Total Measured Counts (including Summation Events) with Exponential Fit  
 
 
 
54 
5.2 Model Validation and Scaling Factors 
 
 
 
As described in §3.2, the ROIs selected to encompass the photopeaks for each of the 
investigated nuclides are given in Table 5.1.1. Additionally, the ROIs for the summation effects 
due to summation peaks for 22Na, 60Co, and 137Cs are also listed in Table 5.1.1. In order to 
preserve the true counts of the full energy gamma reaching the detector, it is imperative to 
redistribute these summed counts back into the photopeak energy region of the measurement for 
comparison with the simulation results. 
 
 
 
Table 5.1.1 Counting Regions of Interest for PMMA Slab Phantom Measurements 
Nuclide Peak Energy 
(keV) 
ROI on 
MCA 
(Channels) 
ROI 
(keV) 
241Am 59.5 [13, 26] [32.6, 73.9] 
133Ba 276.4, 302.9, 356.0 [81, 132] [248.6, 410.6] 
60Co 1173.2, 1332.5 [348, 393] [1096.7, 1411.1] 
2505.7 
(Sum Coincidence Peak) 
[753, 831] [2383.0, 2630.8] 
137Cs 661.7 [188, 233] [588.5, 731.4] 
1323.4 
(Sum Coincidence Peak) 
[382,442] [1204.7, 1395.2] 
54Mn 834.8 [242, 281] [760.0, 883.9] 
22Na 511.0 
(Annihilation Peak) 
[147, 182] [458.2, 569.4] 
1274.5 
 
[370, 432] [1166.5, 1363.5] 
1785.5 
(Sum Coincidence Peak) 
[538, 600] [1700.1, 1897.1] 
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In order to validate the detector model, the ratio of the counts in the ROI photopeak for 
both the experimental and computational results must be constant over all thicknesses of PMMA 
for each of the six radionuclides. For each nuclide, the ratios fluctuate about a mean, and overlap 
with the mean within reasonable error. The six radionuclides were selected to validate the 
detector model over a range of energies and PMMA thicknesses from 0-mm to 90-mm (with the 
exception of 133Ba and 241Am, which were validated up to 60-mm). The results are displayed in 
Figures 5.2.2 through Figure 5.2.8.  
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Figure 5.2.1 241Am Scaling Factor for 59.5-keV Peak ROI 
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Figure 5.2.2 133Ba Scaling Factor for Combined 276.4-keV, 302.9-keV and 356.0-keV Peak 
ROIs 
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Figure 5.2.3 60Co Scaling Factor for Combined 1173.2-keV and 1332.5-keV Peak ROIs 
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Figure 5.2.4 137Cs Scaling Factor for 661.7-keV Peak ROI 
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Figure 5.2.5 54Mn Scaling Factor for 834.8-keV Peak ROI 
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Figure 5.2.6 22Na Scaling Factor for 511-keV Peak ROI 
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Figure 5.2.7 22Na Scaling Factor for 1274.5-keV Peak ROI 
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The mean value about which the ratios fluctuate is referred to as the scaling factor, which 
quantifies the detector efficiency characteristics. These scaling factors vary for different 
individual nuclides, thus indicating an energy-dependent response from the detector. The error 
bars tend to overlap with the mean, and the overall error of all the nuclides fall within 1.35× the 
standard deviation of the mean. Sources of error contributing to the scaling factor error include a 
predominant 3.3% error in the checked source activity, statistical counting error from gross and 
background counts (<0.11% data error), and the pulse-height tally bin error (<0.001%). Once the 
scaling factor is applied to MCNP data, the MCNP output closely resembles the experimental 
data. An example for 137Cs is shown in Figure 5.2.8. 
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Figure 5.2.8 137Cs Slab Phantom Comparison of MCNP to Experimental Count Rates after 
Application of Scaling Factor 
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Statistical outliers for very small thicknesses of PMMA, such as 0-mm with 22Na and 0-
mm and 6-mm for 133Ba and 60Co, were eliminated using Grubbs’ test method, which eliminates 
values that do not fall within the 95% confidence interval of a Gaussian distribution [39]. These 
outliers may be caused by contamination by gamma-ray sources in the surroundings, as well as a 
high activity source that would an increase in summation events and inflating the scaling factor. 
It is permissible to eliminate these outliers at such low thicknesses considering the 
anteriposterior thickness of the MIRD Reference Man has a mass thickness of 4.26-g/cm2 [2]. 
Comparatively, PMMA has a density of 1.19-g/cm3, which corresponds to an equivalent PMMA 
thickness of 35.8-mm. Thus, weighting the data toward more realistic attenuation effects is 
warranted. As a point of comparison, the Reference Male phantom has a chest wall mass 
thickness of 2.18-g/cm2, or 21-mm [2]. In the event of assessing a highly contaminated 
individual, it may even be recommended to not position the detector directly in against the 
patient, in order to mitigate these effects due to high-incident events.  
 From the six isotopes used to determine the energy-dependent response of the detector, 
three are directly applicable to the nuclides of interest used to contaminate the anthropomorphic 
phantoms. However, two nuclides used in the phantom simulations, 131I and 192Ir, were not 
included in the benchmark experiments. Therefore, their scaling factors were extrapolated via an 
energy-dependent linear interpolation based on the benchmark radionuclide scaling factors. Their 
ROIs were determined based on running a simulation with the slab phantom (with 0-mm 
thickness), and the respective 192Ir or 131I source replaced. Since the ROIs are to be arbitrarily 
selected to encompass the peak, any slight variance between the detector and simulated ROIs 
should be inconsequential. The scaling factors employed with the anthropomorphic phantoms are 
summarized in Table 5.2.1. 
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Table 5.2.1 Scaling Factors Employed for Anthropomorphic Phantom Nuclide 
Contaminants 
 
Nuclide Peak ROI Energy 
(keV) 
Scaling Factor 
(MCNP/Experimental) 
241Am 59.5 1.00+0.03 
60Co 1173.2, 1332.5 
 
0.86+0.03 
137Cs 661.7 0.85+0.03 
131I 364.5 0.9+0.1 
192Ir 316.5 0.96+0.06 
 
 
 
Upon simulating the appropriate measurements and obtaining a constant-averaged scaling factor 
from the detector response, the detector model was validated for use with the anthropomorphic 
phantoms.   
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5.3 MIRD Phantom Results 
 
 
 
Upon verification of the detector model, six anthropomorphic phantoms were modeled 
with nuclides distributed throughout select organs for each of the five sources under 
consideration.  After simulation, the data were combined with the time-dependent biokinetic 
modeling to determine the threshold count-rate values expected for individuals with a committed 
effective dose due to 250-mSv of contamination. 
In the MCNP model of the anthropomorphic phantoms, the SCX tally modifier was 
employed to determine the source organ contribution for each source particle that reaches the 
detector. The data resulting from the employment of the SCX tally modifier for the Reference 
Male contaminated with 241Am is depicted in Figure 5.3.1. In the case of 241Am, this figure 
shows that the body tissue and bones are the major source organs contributing to the detector 
counts, as americium is a known bone-seeker.  
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Figure 5.3.1 Male Phantom SCX Source Organ Contribution for 241Am  
(Number of Particles Tallied per Source Particle in Each Organ)  
 
 
 
Once the SCX tally data for each source compartment at each detector location was 
folded with the DCAL biokinetic data, the resulting output was given in counts per Bq of intake 
activity. Applying the dose conversion factors at the 250-mSv action level yields a final result in 
count-rate (cpm) per 250-mSv intake. Each detector location was tallied for each of 241Am, 60Co, 
137Cs, 131I, and 192Ir. A sample of the final count-rates for 137Cs and 131I (with optimal locations 
highlighted) are given in Tables 5.3.1 and 5.3.2. The data for all phantoms and nuclide 
combinations are provided in Appendix C.  
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Table 5.3.1 Count-Rate per 250-mSv Intake for Reference Male Contaminated with 137Cs 
Reference Male: 137Cs F 
Days Posterior 
Right Lung 
(cpm per 250-
mSv Intake) 
Anterior 
Right Lung 
(cpm per 250-
mSv Intake) 
Anterior Neck 
(cpm per 250-
mSv Intake) 
Lateral Left 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 3.58E+04 3.38E+04 5.05E+03 4.81E+01 
0.2 1.37E+05 1.48E+05 9.42E+04 5.02E+04 
0.5 2.14E+05 2.27E+05 1.56E+05 8.28E+04 
1.0 2.55E+05 2.70E+05 1.89E+05 1.00E+05 
2.0 2.62E+05 2.76E+05 1.94E+05 1.03E+05 
3.0 2.57E+05 2.71E+05 1.90E+05 1.01E+05 
4.0 2.52E+05 2.66E+05 1.87E+05 9.94E+04 
5.0 2.48E+05 2.62E+05 1.84E+05 9.78E+04 
6.0 2.45E+05 2.58E+05 1.82E+05 9.66E+04 
7.0 2.42E+05 2.56E+05 1.80E+05 9.55E+04 
8.0 2.40E+05 2.53E+05 1.78E+05 9.46E+04 
9.0 2.38E+05 2.51E+05 1.76E+05 9.38E+04 
10.0 2.36E+05 2.49E+05 1.75E+05 9.30E+04 
 
 
 
 
Table 5.3.2 Count-Rate per 250-mSv Intake for Reference Male Contaminated with 131I 
Reference Male: 131I F 
Days Posterior 
Right Lung 
(cpm per 250-
mSv Intake) 
Anterior 
Right Lung 
(cpm per 250-
mSv Intake) 
Anterior Neck 
(cpm per 250-
mSv Intake) 
Lateral Left 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 3.58E+04 3.38E+04 4.56E+03 2.21E+01 
0.2 2.24E+04 2.76E+04 5.43E+04 5.50E+03 
0.5 1.04E+04 1.38E+04 6.91E+04 2.44E+03 
1.0 3.85E+03 6.19E+03 7.50E+04 7.36E+02 
2.0 2.24E+03 4.14E+03 7.12E+04 3.90E+02 
3.0 2.43E+03 4.17E+03 6.52E+04 5.11E+02 
4.0 2.64E+03 4.24E+03 5.97E+04 6.23E+02 
5.0 2.78E+03 4.26E+03 5.46E+04 7.06E+02 
6.0 2.85E+03 4.22E+03 4.99E+04 7.63E+02 
7.0 2.88E+03 4.13E+03 4.56E+04 7.99E+02 
8.0 2.86E+03 4.02E+03 4.17E+04 8.17E+02 
9.0 2.81E+03 3.88E+03 3.81E+04 8.22E+02 
10.0 2.74E+03 3.72E+03 3.48E+04 8.16E+02 
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The error contribution from the phantom tally outputs is quite small, on the order of 
0.01%. The predominant source of error stems from the scaling factors, listed previously in 
Table 5.2.1. These errors range from approximately 3.5% for the directly computed factors 
employed in the benchmark validation measurements, to as much as 11% for the interpolated 
scaling factors. 
 The optimal location for detector placement in the event of a minimum of 250-mSv of 
uptake is dependent on the nuclide inhaled. A summary of the optimal detector position for each 
phantom-nuclide combination based on the highest yielding count-rates is summarized in Table 
5.3.3. Overall, the location yielding a sufficient, if not optimal, detectable count-rate is the 
posterior right lung. As will be discussed, this was the case for all nuclides, with the exception of 
131I, where the neck location had proven optimal or very close to optimal for all phantoms, as 131I 
is a thyroid-seeker.  
With the optimal locations for the detector identified in Table 5.3.3, a graphical 
comparison of the count-rates at these optimal locations for each phantom is given in Figures 
5.3.2 through 5.3.6. 
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Table 5.3.3 Optimal Detector Location for each Phantom-Nuclide Combination 
 
Phantom Nuclide Anterior Right Torso 
Posterior 
Right Torso 
Anterior 
Neck 
Lateral 
Left Thigh 
Reference 
Male 
241Am  X   
60Co * X   
137Cs X *   
131I   X  
192Ir * X   
Reference 
Female 
241Am  X   
60Co  X   
137Cs  X *  
131I   X  
192Ir  X   
Adipose 
Male 
241Am  X   
60Co  X   
137Cs  * X  
131I   X  
192Ir  X   
Adipose 
Female 
241Am  X   
60Co  X   
137Cs  X * * 
131I   X  
192Ir  X   
Post 
Menopausal 
Adipose 
Female 
241Am  X   
60Co  X   
137Cs  X *  
131I   X  
192Ir  X   
Child 
241Am  X   
60Co  X   
137Cs  X   
131I   X  
192Ir  X   
(X) indicates optimal detector location 
(*) indicates location count-rate notably close to optimal location 
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Figure 5.3.2 Comparison of Count-Rate per Phantom for 241Am at Posterior Right Lung 
Position 
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Figure 5.3.3 Comparison of Count-Rate per Phantom for 60Co at Posterior Right Lung 
Position 
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Figure 5.3.4 Comparison of Count-Rate per Phantom for 137Cs at Posterior Right Lung 
Position 
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Figure 5.3.5 Comparison of Count-Rate per Phantom for 131I at Anterior Neck Position 
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Figure 5.3.6 Comparison of Count-Rate per Phantom for 192Ir at Posterior Right Lung 
Position 
 
 
 
Although body type plays a prominent role in determining detector response and count-
rate, it must also be noted that the contaminant nuclide under consideration also contributes to 
the subsequent detector response by its mode of accumulation in the body. For phantoms with 
the detector optimally located at the posterior right torso position, the child phantom tended to 
yield the highest count rate, due to a thin chest wall and comparatively less attenuation. 
Conversely, the adipose phantoms tended to yield lower count rates, due to increased attenuation 
by a larger chest wall, breast tissue and fat. The lateral left thigh location was not optimal for any 
of the detector locations, though was close for the Adipose Female. Although the thigh 
represents a large form of muscle tissue, and even though many of the source counts for the fast 
absorption nuclides originate from the body tissue (as will be discussed), the thigh was still not 
found to be the optimal location for detection. The neck was determined to be the optimal 
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location for the detection of 131I, though employing the posterior right torso position would also 
yield sufficient counts for assaying contamination. The neck location was optimal in this case, as 
iodine is readily metabolized by the thyroid gland.  
The lowest count-rate from all the sampled nuclides originates from 241Am. The easily 
attenuated low-energy gamma-rays (59.5-keV) permit only a small fraction of the gamma-rays to 
reach the detector, thus resulting in a count-rate per 250-mSv intake of many orders of 
magnitude lower than the other nuclides. As will be discussed in §5.4, none of the count-rates for 
241Am are detectable above the background threshold. Additionally, as seen in Table 4.3.1, the 
inhalation dose coefficient for 241Am is approximately four orders of magnitude lower than those 
of the other nuclides, so 241Am requires a low-activity intake to deliver a considerable dose. In 
the absence of the ability to detect low activities of 241Am, it is quite possible that a considerable 
dose can be delivered by the time the detector can definitively detect an adequate count-rate 
above the background detection limit. Consequently, 241Am is considered undetectable by the 
2x2-NaI(Tl) detector for inhaled contamination.  
The sources of the counts that are being tallied by the detector at each detector location 
are presented in Figures 5.3.7 through 5.3.10, displaying the count-rate per contributing source 
organ at three days after inhalation.  Note that the FRL and BRL acronyms refer to the anterior 
and posterior torso locations, respectively. 
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Figure 5.3.7 Reference Male 60Co Count-Rate per Source Organ at 3 Days 
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Figure 5.3.8 Reference Male 137Cs Count-Rate per Source Organ at 3 Days 
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Figure 5.3.9 Reference Male 131I Count-Rate per Source Organ at 3 Days 
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Figure 5.3.10 Reference Male 192Ir Count-Rate per Source Organ at 3 Days 
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 The behavior of 137Cs shows count-rates closely distributed when comparing the 
phantoms in Figure 5.3.4. The optimal detector location for 137Cs occurs when placed over the 
lung location, even though the source of these counts results from contaminant movement 
through the body tissue, not lung retention (fast absorption type), as seen in Figure 5.3.8. In the 
cases of 192Ir and 60Co, both nuclides have moderate lung absorption types. As seen in Figures 
5.3.7 and 5.3.10 (for 60Co and 192Ir, respectively), both tend to receive most of their counts due to 
contributions from where these nuclides tend to accumulate: the lungs, body tissue, and liver. In 
the case of detecting 131I with the detector, its optimal counting location is when placed over the 
anterior neck, where source counts originate from the thyroid (Figure 5.3.9). Yet, the child 
phantom yields the lowest count rate (Figure 5.3.5) because 131I is rapidly taken up by the thyroid 
gland and proceeds at a faster metabolic rate in a child. Additionally, 131I has a short radiological 
half-life of 8.04 days [20]. 
 For the four detectable nuclides, the majority of the counts tend to originate from either 
the lungs or body tissue. The two detectable nuclides with moderate lung absorptions, 60Co and 
192Ir, have a majority of their counts originating from the lungs. Conversely, the nuclides with 
fast lung absorptions, 131I and 137Cs, a majority of counts originate from the body tissue (with the 
exception of the thyroid uptake of 131I). This is due to the fact that the fast uptake nuclides are 
more rapidly clear the lungs into the body, while the moderate uptake nuclides linger for longer 
in the lungs. As previously mentioned with 137Cs, even though the lung and neck locations yield 
optimal count-rates (Table 5.3.3), this is not due to retention in the lungs, but due to counts from 
the inhaled contaminant having metabolized in the body tissue and emitted gammas over these 
large areas of tissue. 
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 Unlike the 2x2 NaI(Tl) detector, the Thyroid Uptake Probe study by Scarboro, which also 
employs a 2x2 NaI(Tl) crystal, was able to limit this “shine” from body tissue due to the 
presence of the lead collimator [15]. Additionally, the subtraction of the ET1 and ET2 
compartments from the DCAL calculation was not applied in Scarboro’s study, resulting in a 
higher lung contribution to the total fraction retained. Therefore, both these reasons contribute to 
why Scarboro’s study determined that the anterior neck was the optimal location for detecting 
137Cs .With the exception of the 137Cs case, the Scarboro study yielded results consistent with 
this study (though lower count-rates) in determining the optimal detector locations to detect 
inhaled contamination. 
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5.4 Consideration of Minimum Detectable Activity, Dose, and Decision Levels 
 
 
5.4.1 Decision Levels 
 
 
 
 Since radioactivity count-rates tend to fluctuate statistically, a minimum threshold must 
be established to discern a lower limit of detection with confidence above background levels. 
The Minimum Detectable Activity (MDA) is used to describe the decision level (DL) for a 
detector counting system in terms of activity. It serves to determine the smallest signal that can 
be reliably detected above the threshold activity of a background sample. The DL is a method 
identifying whether or not a sample is above background levels. The MDA measures the 
detection capability of the counting system, and determines the minimum activity based on a DL. 
Measurements taken on a blank sample provide an a priori estimate of the DL. This estimate, 
based on background measurements, does not serve as a decision-making mechanism, but rather 
describes the detection capability and sensitivity of the system. Thus, a DL must be established 
to determine the net count-rate of a sample above background with a pre-established confidence 
interval. This DL takes the form of Equation 5.4.1.1 [40]. 
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1 11.645 ( )b
b g
DL R
t t
= +     [Equation 5.4.1.1] 
 In this equation, 
  DL = decision level (cpm) 
  Rb = background count rate (cpm) 
  tb = background acquisition time (min) 
  tg = sample acquisition time (min) 
 
When calculation of the DL is applied to measurements from an actual sample, this a 
posteriori calculation provides an estimate of the activity above the background rate, and varies 
according to the nuclide to be detected. As seen in Equation 5.4.1.1, the DL is dependent upon 
the background counting rates, as well as the background and gross sample acquisition times. 
 Since the DL is dependent on the background rates, it is consequently dependent on the 
nuclide and the ROI over which the background spectrum is taken. Using the ROIs given in 
Table 5.1.1, the nuclide-dependent DL above background can be used to determine if real 
activity is present. These nuclide-dependent decision levels were determined using Equation 
5.4.1.1, and are summarized in Table 5.4.1.1 for one-, five-, and ten-minute sample counting 
times. 
 
 
 
77 
Table 5.4.1.1 Minimum Detectable Decision Levels for Various Counting Times for 2x2-
NaI(Tl) Detector 
 
Nuclide Background 
Rate in ROI 
(cpm) 
Decision Level (Above Background)  
for Various Acquisition Times  
(cpm) 
1 minute 5 minutes 10 minutes  
241Am 728.2 44.5 20.1 14.4 
60Co 969.1 51.4 23.2 16.6 
137Cs 542.8 38.4 17.4 12.5 
131I 1784.8 69.7 31.5 22.6 
192Ir 3701.5 100.4 45.4 32.5 
 
 
 
As previously mentioned in §5.3, 241Am has been deemed undetectable by the 2x2-
NaI(Tl) detector. The order of magnitude of the resulting count-rates from each of the phantoms 
(summarized in Appendix D) does not exceed 10-cpm. However, as required in Table 5.4.1.1, a 
count-rate of at least 44.5-cpm above background is required to justify the presence of true 
activity within 95% confidence intervals. In addition, as previously emphasized, 241Am has a 
very high inhalation dose coefficient; by the time this count-rate may be met, a severe dose may 
already have been delivered. In order to adequately detect 241Am, Table 5.4.1 indicates an assay 
acquisition time well exceeding 10-minutes. However, this condition is very impractical for 
triaging purposes. 
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5.4.2 Consideration of Minimum Detectable Activity 
 
This DL estimation is concerned with whether the observed signal is real within a given 
confidence interval. The DL applied in the MDA calculation corresponds to determining the 
threshold for a 5% false alarm rate, a common baseline in detection assessments. Consequently, 
if the net count-rate falls below a DL, it is safe to assume that no real activity is present. The 
MDA equation governing a 5% false-negative rate is given in Equation 5.4.2.1 [40].  
 
 
3 3.29 (1 )gb g
b
g
t
R t
t
MDA
Kt
+ +
=    [Equation 5.4.2.1] 
In this equation, 
 MDA = minimum detectable activity (Bq or µCi) 
 K = counting efficiency 
 
To reiterate, the MDA should only be used as a performance indicator for a detection system, 
whereas the DL indicates the presence of true activity in the system. 
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5.4.3 Minimum Detectable Dose 
 
 
 
 The Minimum Detectable Dose (MDD) is a quantity useful for assessing the detection 
capability for a bioassay system. The MDD is proportional to the MDA, and additionally 
incorporates biological processes and the half-life, as well as the nuclide retention fraction. The 
MDD is governed by Equation 5.4.3.1 [40]. 
 
,50( ) ERC bio u
MDAMDD h
Y V IRF t
= ×
∆
  [Equation 5.4.3.1] 
  
 In this equation,  
  YRC = radiochemical yield of nuclide 
  Vbio = biological variability in excretion rates and volumes 
  IRFu = intake retention fraction 
  ∆t = time between intake and bioassay measurement 
  hE,50 = 50-year committed effective dose equivalent per unit intake 
 
MDA and MDD values were not directly pertinent to the scope of this work and therefore were 
not calculated. However, the MDA and MDD values scaffold on the calculated DLs, which are 
sufficient for the scope of the work addressed herein. 
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5.5 Triaging Procedure Sheets for First Responders 
 
 
 
 In order to employ these results in a first-responder scenario, a set of procedure sheets 
were developed to facilitate triaging decisions using the 2x2-NaI(Tl) detector. Such procedure 
sheets provide a succinct and portable method of communicating how to properly use the 
detector to assess inhaled contamination, as well as to identify individuals requiring further 
medical attention based on the count-rates indicating 250-mSv of contamination. A detector 
location at the posterior right torso position was selected, as this position yields a sufficient 
count-rate for all the investigated nuclides. Opting for a single detector location, regardless of the 
nuclide in question, is convenient as it eliminates operator error in detector placement for 
different nuclides. A procedure sheet was created for each of the six anthropomorphic phantom 
body types and contained in each sheet was a summary of all the four detectable nuclides of 
concern. A sample of the triage procedure sheet for the Reference Male phantom is given in 
Appendix D. 
 Each procedure sheet contains five sections instructing the operator in the use of the 2x2-
NaI(Tl) detector for triage screening. The first section includes a photograph of the detector, such 
that an operator is able to identify the instrument. The second section includes basic information 
on the operation of the detector, as well as how to set-up ROIs depending on the interrogated 
nuclide. The third section instructs the operator how to take a background measurement using the 
instrument, and how to determine a count-rate in cpm.  
 The fourth section instructs the operator on how to obtain a gross count-rate using the 
posterior right torso position, and how to convert this into a net count-rate by subtracting 
background. A decision level of 100-cpm was set as the detection threshold for all radionuclides 
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(based on Table  5.4.4.1), in order to establish a conservative identification of true activity. In 
addition to detection thresholds, in order to mitigate some of the summation and pile-up effects 
mentioned in §5.2, an upper dead-time limit for detection was additionally outlined as a 
secondary method to assess the limitations of the detector system. These dead-time thresholds 
were obtained by analyzing the resulting dead-time for high count-rates. These dead-time 
thresholds were based on the highest expected count-rate per nuclide from the Tables in 
Appendix C. Therefore, dead-time can also be used as an auxiliary indicator of activity incident 
on the detector, though this quantity is certainly dependent on the individual detector, as well as 
source-detector geometry. 
 Finally, the fifth section contains a table of the action levels (net count-rate) for each 
nuclide. The data has been presented for each detectable nuclide in counts-per-minute 
corresponding to 250-mSv of contamination as the triage threshold. Procedure sheets were 
created for each of the six anthropomorphic body types with a summary of all four of the 
detectable nuclides of concern.  
 In order to further optimize the triaging procedure using the instructional sheets, 
Manger’s analysis for triage with Geiger-Mueller counters [41] has recommended that it may be 
prudent to combine all the adult phantoms into a single category. Determining the body type that 
best suits a triage patient is highly subjective and introduces a strong element of operator error. 
Discerning a Pre-Menopausal from a Post-Menopausal Adipose Female, for example, is intrusive 
and time consuming. Thus, such semantics can be avoided if the adults were collected into a 
single adult class, utilizing the most conservative phantom’s data set (Adipose Male) for the 
posterior lung position. This adds additional elements of safety, as the most conservative triaging 
thresholds are employed, thus reducing the probability of false negatives for most of the adult 
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phantoms. Ultimately, the operator is left only to decide if the triage patient is an adult or child. 
Applying this procedure reduces the need for six triage procedure sheets into a single 
consolidated sheet containing the conservative adult (Adipose Male) counting thresholds, as well 
as those of the child. The condensed triage procedure sheet is given in Appendix E. 
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CHAPTER 6:  CONCLUSIONS 
 
 
 
 The 802-2x2-Na(Tl) detector is capable of assaying individuals having inhaled 
contamination for triage purposes if exposed to an RDD. The detector is capable of assaying the 
four of the five nuclides investigated: 60Co, 137Cs, 131I, and 192Ir. However, 241Am did not meet 
minimum detection thresholds to ensure true count-rates were present for at least 250-mSv of 
contamination, and consequently cannot be detected by 2x2-NaI(Tl) detectors. The easily 
attenuated low energy gamma-rays emitted by 241Am, as well as its high dose coefficient, make it 
difficult to detect. 
 In the event that the 2x2-NaI(Tl) detector needed to be employed in an emergency 
scenario by first responders, it is recommended that more time be dedicated to identifying and 
counting the contaminant, rather than applying demographics to associate the patient with the 
appropriate phantom body-type. Placing the detector at the posterior right torso position yields 
sufficient, if not optimal, counts for all the nuclides investigated. Using the most conservative 
count-rate from the phantoms at this detector location would provide a simple and conservative 
estimate of contamination, while eliminating human decision-making errors by the operator 
when attempting to determine body-type or detector location. In this respect, using the most 
conservative count-rates at the optimal detector location would involve using the posterior right 
torso position for the Adipose Male. The Child phantom count-rates at the posterior right torso 
position may be employed for children to satisfy the distinct variation in body type from the 
adult phantoms. 
 For a threshold contamination of 250-mSv, a minimum counting time of one-minute is 
sufficient in discerning true activity above background for each of the four detectable nuclides. 
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Yet, given the complex nature of the instrument and the calibration required, it is strongly 
recommended that trained personnel with experience using sodium-iodide detectors conduct the 
set-up before and conduct supervision during use by first responders. The detector itself is not 
hand-portable, and requires the set-up of modules, energy calibrations, and ROI determination. 
Therefore, only with the assistance technical personnel experienced in operating sodium-iodide 
detectors is the 2x2-NaI(Tl) is feasible for triaging individuals exposed to an RDD. Yet, although 
the sodium-iodide is amply capable of doing so, it is the recommendation of this study that it is 
not to be used if given more easily operable detector alternatives. Sensitivity, detector set-up, 
summation coincident events, and pulse pile-up all become prominent issues best dealt with in a 
laboratory, rather than a field setting. These detectors are not intuitive, even with operation by 
experienced personnel. Field conditions will likely complicate the data acquisition and analysis 
process, as multiple data acquisitions were required to obtain the slab benchmark measurements 
in a controlled laboratory setting. Recommendations made in the next section for future work 
will mitigate the complexities when operating a sodium-iodide detector. 
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CHAPTER 7:  FUTURE WORK 
 
 
 
 Given the concerns mentioned in the previous section, future work must be dedicated 
towards making the sodium-iodide detector more user-friendly. Thus, it is recommended that an 
independent software platform be created that is capable of processing background spectra data 
inputs, and even manual entry of the ROI for the nuclide of interest. Based on such information, 
assay data can be fed into a graphical-user interface and return a computed result, even of a 
Boolean “contaminated”/“not contaminated” nature, thus reducing operator error. Although 
companies such as Canberra offer their own detection software like Genie, it would be advisable 
to develop an independent graphical interface that may work in conjunction with the data 
obtained using the manufacturer’s software. This is a very feasible solution that would greatly 
increase the accessibility and usability of this detector instrument. 
 Further work using the NaI(Tl) detector can be focused on investigating the effects if 
more than one radionuclide (combination) was to be inhaled by a patient. Sodium-iodide 
detectors are customizable spectrometers that would be optimal in such a scenario, as a 
spectrometer is capable of isolating different ROIs, and thus determining each nuclide’s 
contribution with inhalation dose coefficients. Investigating these summed effects of multiple 
inhaled contaminants would be an additional strong study of interest. 
 Finally, future work must be focused on developing a method to detect 241Am. The 
inability to detect this nuclide, in conjunction with its high dose coefficient and ability to deliver 
a high dose at a low activity, is of imminent concern. Further investigating the capabilities of the 
sodium-iodide detector using longer counting times or alternative methods is suggested, as well 
as developing an alternative detection method to reliably detect 241Am, in general, is paramount. 
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APPENDIX A: MCNP INPUT FILE FOR SLAB PHANTOM 
 
 
 
87 
NaI 2x2 Model of PMMA Slabs, Virtual Water, and Detector 
C Cell Cards 
1 4 -3.667       -5       imp:p=1  $ NaI Crystal 
2 9 -.55       5 -10    imp:p=1  $Al2O3 
3 1 -2.94       10 -11  imp:p=1  $Al Window 
4 3 -0.93       11 -9    imp:p=1   $Foam 
5 2  -0.94      -3     imp:p=1  $ PMT Glass 
6 0            -2 9 10 11 3   imp:p=1  $ PMT Vacuum 
7 1  -2.94  -98 -1 2 9 10 11   imp:p=1  $ Al Casing 
8 5  -1.19      -6         imp:p=1   $ PMMA in front of source 
9 8 -1           -4  6     imp:p=1   $Source 
10 5  -1.19     4 -7     imp:p=1   $ PMMA with source 
11 6  -1.03     -8        imp:p=1   $Virtual water behind source 
12 7  -1.293e-3  -98 1 6 7 8     imp:p=1  $ Air Environment 
13 0             98  imp:p=0  $Universe 
 
C Surface Cards 
1 RCC    0      0     0    -18.41 0     0    2.94     $ Al Casing 
2 RCC   -0.2   0     0    -18.01 0     0    2.74   $ PMT Vacuum 
9 RCC   -0.2   0     0    -.2   0      0    2.74   $ Foam 
11 RCC  -.4   0     0    -.05   0      0    2.74  $ Al Window 
10 RCC  -.45  0      0    -5.26  0     0    2.74   $ Al2O3 
5 RCC   -.61    0    0    -5.1      0     0    2.55      $ NaI Crystal  
3 RCC   -5.71  0     0    -0.3      0     0    2.74      $ 0.3cm PMT Glass 
4 RCC   0.8   -1.15   0      0       2.3   0     .2      $ Source 
6  RPP   0.0    0.6  -15.3   15.3  -15.2   15.2     $ PMMA in front of source 
7  RPP   0.6    1.2  -15.3   15.3  -15.2   15.2     $ PMMA with source 
8  RPP   1.2   11.2  -15.3   15.3  -15.2   15.2     $ Virtual water 
98 RPP   -50    50   -50     50    -50     50       $ Air Environment 
 
C Data Cards 
C 
C Material Cards 
C 
C Al Casing 
m1 13027 1 
C Low Density Glass 
m2 14000 0.3333 8016 0.6667 
C Foam + 0.01 g/cc  
m3 1001 0.6667 6000 0.3333 
C NaI Crystal 2X2 
m4 11000.04p 0.5 53000.04p 0.5 
C m4 11023 0.5 53127 0.5 
C PMMA 
m5 6000 0.3333 8016 0.1333 1001 0.5334 
C Virtual Water 
m6 1001 0.0802 6000 0.6748 7015 0.0214 8016 0.1991 & 
   17000 0.0014 20000 0.0231 
C Air 
m7 8016 -0.2314 7014 -0.7558 18000 -0.0128 
C Polyester for Sources 
m8 6000 0.333 1001 0.533 8016 0.133 
C Al2O3 
m9 13027 0.4 8016 0.6 
C 
C Source Cards 
88 
C 
SDEF par=2 rad=d1 pos=0.8 0.0 0.0 axs=0 1 0 vec=0 0 1 erg=d3 ext=d2 
SI1 0 0.2 
SP1 -21 1 
SI2 -1.15 1.15 
SP2 -21 0 
C 
C Cs-137 0.662MeV 
SI3 l 0.661645 
SP3 0.851 
C 
C SI3 l 0.834827 
C SP3   0.99976 
C 
C Tally Cards 
C 
F8:p 1 $ Tally over NaI Crystal 
fc8 F8 tally no GEB 
F18:p 1 
fc18 F8 tally with GEB 
C 
C Energy Bins 
C 
E0 0 1e-8 .000876 1020i 3.243776 $1022 Channels 
C 
C Gaussian Energy Broadening 
C 
FT18 GEB -0.00715076 0.0652825 -0.178934 $ GEB Values 
C 
phys:p 4j 1 
mode p 
print 
nps 5e7  
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APPENDIX B: MCNP INPUT FILE FOR ANTHROPOMORPHIC 
PHANTOM 
90 
Male With Cs-137 
1     1 -.001293    -1 (607:-37:606) (-606:601:35) (600:-35) & 
                    (-615:37:-43:44:4:-616) (37:-608:609) & 
                    (37:-608:610) 900 901 902 903 
2     2 -0.2958     ((-2 -4 3):(-2 4)) 5                                  $ left lung 
3     3 -0.9869     -7 51 -6 (-8:32) 84 101 #2 #24 #28 #58 #59 
                    (113:115) (114:115) #62 #700                          $ torso insd ribs/lvrtop-shldr 
4     3 -0.9869     -7 8 -32 117 113 114 #15 #16 #17 #18 #19 #20 #700 
                    (-4:-9:116:118:-119) (-4:-9:116:120:-121)             $torso 
5     3 -0.9869     -7 8 -117 51 113 114 #9 #13 #14 #700                  $ torso 
6     3 -0.9869     -7 50 -51 56 84 96 105 106 113 114 #10 #11 #12 
                    #27 #32 #43 #44 #47 #700                              $ torso 
7     3 -0.9869     -7 97 -50 (83:-86:87:-88) 113 114 #30 #33 #38 #39 
                    #63 #64 #65 #700                                      $ torso abdomen 
8     3 -0.9869     -7 37 -97 95 113 114 #31 #33 #38 #65 #66 #700         $ torso abdomen 
9     4 -1.4862     8 -9 5 -10                                            $ rib 
10    4 -1.4862     8 -9 11 -12                                           $ rib 
11    4 -1.4862     8 -9 13 -14                                           $ rib 
12    4 -1.4862     8 -9 15 -16                                           $ rib 
13    4 -1.4862     8 -9 17 -18                                           $ rib 
14    4 -1.4862     8 -9 19 -20                                           $ rib 
15    4 -1.4862     8 -9 21 -22                                           $ rib 
16    4 -1.4862     8 -9 23 -24                                           $ rib 
17    4 -1.4862     8 -9 25 -26                                           $ rib 
18    4 -1.4862     8 -9 27 -28                                           $ rib 
19    4 -1.4862     8 -9 29 -30                                           $ rib 
20    4 -1.4862     8 -9 31 -32                                           $ rib 
21    3 -0.9869     ((35 -34):(-33 6 -35)) 102 (84:85) 
                    #37 #60 #61 #62 #700                                  $ head 
22    3 -0.9869     -37 38 -39 103 #700                                   $ left leg 
23    3 -0.9869     -37 38 -40 104 #22 #700                               $ right leg 
24    2 -0.2958     ((-41 -4 42):(-41 4)) 5                               $ right lung 
25    3 -0.9869     715 -37 43 -44 -4 716 39 40 72 73 #700 #600           $ genitalia 
26    3 -0.9869     -47                                                   $ brain 
27    3 -0.9869     50 -51 -48 -49 #10 #11 #12                            $ liver 
28    3 -0.9869     (-52 54):(-53 -54 55)                                 $ heart 
29    3 -0.9869     -56                                                   $ stomach 
30    3 -0.9869     138 -57 58 -59                                        $ Ascending Colon Wall  
31    3 -0.9869     (-63 141 65 -61):(-64 142 37 -65)                     $ Sigmoid Colon Wall 
32    3 -0.9869     -62 139 66 -67 59                                     $ Transverse Colon Wall 
33    3 -0.9869     -60 140 61 -59 -83                                    $ Descending Colon Wall 
35    3 -0.9869     -72                                                   $ testicle 
36    3 -0.9869     -73                                                   $ testicle 
37    3 -0.9869     -74 75 -76 6 -77                                      $ thyroid 
38    4 -1.4862     -82 83 37 -78 80 (79:-81)                             $ pelvis 
39    4 -1.4862     -84 78 -85 102                                        $ spine 
40    3 -0.9869     -83 86 -50 88 -87 #30 #32 #33 #63 #64 #65             $ small int. 
41    1 -0.001293   -107 606 -4                                           $ air 
42    1 -0.001293   -108 606 -4                                           $ air 
43    3 -0.9869     -92 65                                                $ kidney 
44    3 -0.9869     -93 -94                                               $ kidney 
45    3 -0.9869     -95                                                   $ bladder 
46    3 -0.9869     -96                                                   $ spleen 
47    3 -0.9869     -98 99 (-65:100)                                      $ pancreas 
48    3 -0.9869     -101                                                  $ thymus 
49    4 -1.4862     47 -102 #60 #61                                       $ skull 
91 
50    4 -1.4862     -103 38 -37                                           $ leg bone 
51    4 -1.4862     -104 38 -37                                           $ leg bone 
52    3 -0.9869     -105 92                                               $ adrenal 
53    3 -0.9869     -106 93                                               $ adrenal 
54    4 -1.4862     37 -115 -113                                          $ arm bone 
55    4 -1.4862     37 -115 -114                                          $ arm bone 
56    4 -1.4862     4 9 -32 -116 117 -118 119                             $ scapulae 
57    4 -1.4862     4 9 -32 -116 117 -120 121                             $ scapulae 
58    4 -1.4862     -4 -122 -123 124                                      $ clavicle 
59    4 -1.4862     -4 -122 -125 126                                      $ clavicle 
60    3 -0.9869     -33 128 129 -130 133 -134 -4 #700                     $ eye lens 
61    3 -0.9869     -33 128 -131 132 133 -134 -4 #700                     $ eye lens 
62    3 -0.9869     -77 -137 51                                           $ esophagus 
63    3 -0.9869     -138 58 -59                                           $ Ascending Colon Interior  
64    3 -0.9869     -139 66 -67                                           $ Transverse Colon Interior 
65    3 -0.9869     -140 61 -59 -83                                       $ Descending Colon Interior 
66    3 -0.9869     (-141 65 -61) : (-142 37 -65)                         $ Sigmoid Colon Interior 
600   0             -600 35 34 902 : -601 33 -35 606 902 : &                $ Head & Neck 
                    -606 6 33 -607 902: -607 7 -6 37 900 901 902 : &   $ Shoulders & Torso 
  (((-46 616) (43 -44) (615 -37)):((615 -45)(610 609)(46 -4)(43 -44))): & $ Genitalia 
                    -610 40 -37 38 : -609 39 -37 38 903: &                $ Legs 
                    -708 608 -609 : -708 608 -610 : &                     $ Feet 
                    -38 708 -610 40 : -38 708 -609 39                      
700   5 -1.04       700 35 102 -34 : 701 -33 -35 6 : &                    $ Head & Neck 
                    706 -6 701 -707 : 707 -7 -6 37 114 113 : &            $ Shoulders & Torso 
  (((46 -716)(43 -44)(609 610)(715 -37)):((-715 45)(610 609)(46 -4)(43 -44))): & $ Genitalia 
                    -40 710 -37 38 : -39 709 -37 38 : &                   $ Legs 
                    -38 708 -39 : -38 708 -40                             $ Feet 
900   1 -.001293    -900 7 501 
901   1 -.001293    -901 7 511 
902   1 -.001293    -902 6 33 34 521 
903   1 -.001293    -903 39 531 
c Detector in box 900 NaI 2x2 
c Detector in box 900 NaI 2x2 
501 504 -3.667  -505                              $ NaI Crystal 
502 509 -.55     505 -507                         $ Al2O3 
503 501 -2.94    507 -506                         $ Al Window 
504 503 -0.93    506 -509                         $ Foam 
505 502 -0.94   -503                              $ PMT Glass 
506 0           -502  509  507  506  503          $ PMT Vacuum 
507 501 -2.94   -900 -501  502  509  507  506     $ Al Casing 
c Detector in box 901 
511 504 -3.667  -515                              $ NaI Crystal 
512 509 -.55     515 -517                         $ Al2O3 
513 501 -2.94    517 -516                         $ Al Window 
514 503 -0.93    516 -519                         $ Foam 
515 502 -0.94   -513                              $ PMT Glass 
516 0           -512  519  517  516  513          $ PMT Vacuum 
517 501 -2.94   -901 -511  512  519  517  516     $ Al Casing 
c Detector in box 902 
521 504 -3.667  -525                              $ NaI Crystal 
522 509 -.55     525 -527                         $ Al2O3 
523 501 -2.94    527 -526                         $ Al Window 
524 503 -0.93    526 -529                         $ Foam 
525 502 -0.94   -523                              $ PMT Glass 
526 0           -522  529  527  526  523          $ PMT Vacuum 
92 
527 501 -2.94   -902 -521  522  529  527  526     $ Al Casing 
c Detector in box 903 
531 504 -3.667  -535                              $ NaI Crystal 
532 509 -.55     535 -537                         $ Al2O3 
533 501 -2.94    537 -536                         $ Al Window 
534 503 -0.93    536 -539                         $ Foam 
535 502 -0.94   -533                              $ PMT Glass 
536 0           -532  539  537  536  533          $ PMT Vacuum 
537 501 -2.94   -903 -531  532  539  537  536     $ Al Casing 
67    0             1 
 
1     SO  200 
2     SQ  23.04 10.24 1 0 0 0 -576 8.5 0 43.5 
3     SQ  23.04 10.24 1 0 0 0 -576 2.5 0 43.5 
4     PY  0.0 
5     PZ  43.5 
6     PZ  70 
706   PZ  69.8 
606   PZ  70.2 
7     SQ  1 4.0 0 0 0 0 -400.0 0 0 0 
707   SQ  0.002551 0.010412 0 0 0 0 -1 0 0 0  
607   SQ  0.002451 0.00961  0 0 0 0 -1 0 0 0  
8     SQ  1 3.15 0 0 0 0 -272.25 0 0 0 
9     SQ  1 3.01 0 0 0 0 -289.0 0 0 0 
10    PZ  44.9 
11    PZ  35.1 
12    PZ  36.5 
13    PZ  37.9 
14    PZ  39.3 
15    PZ  40.7 
16    PZ  42.1 
17    PZ  46.3 
18    PZ  47.7 
19    PZ  49.1 
20    PZ  50.5 
21    PZ  51.9 
22    PZ  53.3 
23    PZ  54.7 
24    PZ  56.1 
25    PZ  57.5 
26    PZ  58.9 
27    PZ  60.3 
28    PZ  61.7 
29    PZ  63.1 
30    PZ  64.5 
31    PZ  65.9 
32    PZ  67.3 
33    SQ  100 49 0 0 0 0 -4900 0 0 0 
701   SQ  0.021626 0.010412 0 0 0 0 -1 0 0 0 
601   SQ  0.01929 0.009612 0 0 0 0 -1 0 0 0 
34    SQ  7225 3540.25 4900 0 0 0 -354025 0 0 85.5 
700   SQ  0.021626 0.010412 0.014516 0 0 0 -1 0 0 85.5 
600   SQ  0.01929 0.009612 0.013212 0 0 0 -1 0 0 85.5 
35    PZ  85.5 
36    PZ  94 
37    PZ  0 
93 
38    PZ  -80 
708   PZ  -80.215 
608   PZ  -80.415 
39  601  GQ  5.025 5 0 0 0 -1 -100 0 0 0 
709 603  GQ  5.05 5 0 0 0 -1 -100 0 0 0 
609 605  GQ  4.963 5 0 0 0 -1 -100 0 0 0 
40  600  GQ  5.025 5 0 0 0 1 100 0 0 0 
710 602  GQ  5.089 5 0 0 0 1 100 0 0 0 
610 604  GQ  4.963 5 0 0 0 1 100 0 0 0 
41    SQ  23.04 10.24 1 0 0 0 -576 -8.5 0 43.5 
42    SQ  23.04 10.24 1 0 0 0 -576 -2.5 0 43.5 
43    P   10 0 1 -100 
44    P   10 0 -1 100 
45    PZ  -4.8 
715   PZ  -4.6 
615   PZ  -5.0 
46    P   0 10 1 -100 
716   P   0 10.2 1 -100 
616   P   0 9.8 1 -100 
47    SQ  2.25 1 1.91716 0 0 0 -81 0 0 86.5 
48    SQ  64 272.25 0 0 0 0 -17424 0 0 0 
49    P   9 7 -7.3256 -315 
50    PZ  27 
51    PZ  43 
52    GQ  45.2 59.9 47.9 17.5 -16.2 34.8 -1632.1 1204.8 -4898.2 124295.2 
53    SQ  1 1 1 0 0 0 -25 -1 -3 51 
54    P   .6943 -.3237 -.6428 -32.506 
55    P   5.2193 -2.4336 -0.916 -59.6345 
56    SQ  4 7.11 1 0 0 0 -64 8 -4 35 
57    SQ  1 1 0 0 0 0 -6.25 -8.5 -2.36 0 
58    PZ  14.45 
59    PZ  24 
60    GQ  4.54 3.53 .096 0 1.16 -0.166 -77.68 -10.08 -.223 323.52 
61    PZ  8.72 
62    SQ  0 2.25 6.25 0 0 0 -14.0625 0 -2.36 25.5 
63    TY  3 0 8.72 5.72 1.57 1.57 
64    TY  3 0 0 3 1.57 1.57 
65    PX  3 
66    PX  -10.5 
67    PX  10.5 
68    PX  -20 
69    PX  20 
70    PY  -30 
71    PY  -29 
72    SQ  11.9025 8.9401 3.8025 0 0 0 -20.115225 1.3 -8 -2.3 
73    SQ  11.9025 8.9401 3.8025 0 0 0 -20.115225 -1.3 -8 -2.3 
74    C/Z 0 -6 2.2 
75    C/Z 0 -6 1 
76    PY  -6 
77    PZ  75 
78    PZ  22 
79    PZ  14 
80    PY  -3 
81    PY  5 
82    C/Z 0 -3 12 
83    C/Z 0 -3.8 11.3 
94 
84    SQ  6.25 4 0 0 0 0 -25 0 5.5 0 
85    PZ  78.5 
86    PZ  17 
87    PY  2.2 
88    PY  -4.86 
89    C/Z 0 -11. 0.6350 
90    C/Z 0 -11. 0.8636 
91    PZ  56.335 
92    SQ  1.49 13.44 1 0 0 0 -30.25 6 6 32.5 
93    SQ  1.49 13.44 1 0 0 0 -30.25 -6 6 32.5 
94    PX  -3 
95    SQ  1 2.0557 2.0557 0 0 0 -24.5818 0 -4.5 8 
96    SQ  2.94 9 1 0 0 0 -36 11 3 37 
97    PZ  12 
98    SQ  1 225 25 0 0 0 -225 0 0 37 
99    PX  0 
100   PZ  37 
101   SQ  1.78 64 1 0 0 0 -16 -2 -6 60.5 
102   SQ  2.08 1 1.39 0 0 0 -96.04 0 0 85.5 
103   GQ  1 1 .0091 0 0 -.2005 -20 0 1.7857 87.75 
104   GQ  1 1 .0091 0 0 .2005 20 0 1.7857 87.75 
105   SQ  100 900 9 0 0 0 -225 4.5 6.5 38 
106   SQ  100 900 9 0 0 0 -225 -4.5 6.5 38 
107   SQ  1.39 .5 2 0 0 0 -70 -6.5 -3 50 
108   SQ  1.39 .5 2 0 0 0 -70 6.5 -3 50 
109   PX  17 
110   PX  6 
111   PX  -6 
112   PX  -17 
113   GQ  503.01 135.24 0 0 0 10.206 -19215 0 -202.0788 183257 
114   GQ  503.01 135.24 0 0 0 -10.206 19215 0 -202.0788 183257 
115   PZ  69 
116   SQ  1 3.7589 0 0 0 0 -361 0 0 0 
117   PZ  50.9 
118   P   0.25 -1 0 0 
119   P   0.8 -1 0 0 
120   P   -0.25 -1 0 0 
121   P   -0.8 -1 0 0 
122   TZ  0 11.1 68.25 20 0.7883 0.7883 
123   P   0.89415 1 0 11.1 
124   P   7.0342 1 0 11.1 
125   P   -0.89415 1 0 11.1 
126   P   -7.0342 1 0 11.1 
C      2 concentric elliptical cylinders and planes to define eye lenses 
127   SQ  100 64 0 0 0 0 -6400 0 0 0 
128   SQ  88.36 40.96 0 0 0 0 -3619.2256 0 0 0 
129   PX  2 
130   PX  4 
131   PX  -2 
132   PX  -4 
133   PZ  82.5 
134   PZ  84.5 
C      segmenting planes for RBM regions in leg and arm bones 
135   PZ  -22.8 
136   PZ  52.6 
C      Esophagus 
95 
137   SQ 0.16 1.0 0 0 0 0 -0.16 0.5 2.5 0                            $ Esophagus Exterior 
C      Colon Wall 
138   SQ 1 1 0 0 0 0 -3.209 -8.5 -2.36 0                             $ Ascending Colon Interior 
139   SQ 0 0.9467 3.8927 0 0 0 -3.6854 0 -2.36 25.5 
140   GQ 1.796 2.496 0.0674 0 0.818 -0.066 -30.75 -7.12 -0.602 132.2 
141   TY 3 0 8.72 5.72 0.91 0.91                                     $ Upper Sigmoid Interior 
142   TY 3 0 0 3 0.91 0.91                                           $ Lower Sigmoid Interior 
C Boxes for Detectors 
900 900 BOX 0.39 10.9607 38.36   -17.78 0 0 & 
        0 50.8 0      0 0 17.78 
901 901 BOX 0.39 -10.9609 38.35  -17.78 0 0 & 
        0 -50.8 0     0 0 17.80 
902 BOX -8.89 -10 70.01  17.78 0 0  0 -50.8 0   0 0 17.78 
903 903 BOX 19.98 -8.89 0  50.8 0 0  0 17.78 0  0 0 -17.78 
c 
c c 
c Detector in Box 900 
c c 
c 
C Surface Cards 
501 501 RCC    0    0   0    -18.41 0   0    2.94  $ Al Casing 
502 501 RCC   -0.2  0   0    -18.01 0   0    2.74  $ PMT Vacuum 
509 501 RCC   -0.2  0   0    -0.2   0   0    2.74  $ Foam 0.2cm 
506 501 RCC   -0.4  0   0    -0.05  0   0    2.74  $ Al Window 
507 501 RCC   -0.45 0   0    -5.26  0   0    2.74  $ Al2O3 0.16cm 
505 501 RCC   -0.61 0   0    -5.1   0   0    2.55  $ NaI Crystal  
503 501 RCC   -5.71 0   0    -0.3   0   0    2.74  $ 0.3cm PMT Glass 
c 
c c 
c Detector in Box 901 
c c 
511 502 RCC    0    0   0    -18.41 0   0    2.94  $ Al Casing 
512 502 RCC   -0.2  0   0    -18.01 0   0    2.74  $ PMT Vacuum 
519 502 RCC   -0.2  0   0    -0.2   0   0    2.74  $ Foam 0.2cm 
516 502 RCC   -0.4  0   0    -0.05  0   0    2.74  $ Al Window 
517 502 RCC   -0.45 0   0    -5.26  0   0    2.74  $ Al2O3 0.16cm 
515 502 RCC   -0.61 0   0    -5.1   0   0    2.55  $ NaI Crystal  
513 502 RCC   -5.71 0   0    -0.3   0   0    2.74  $ 0.3cm PMT Glass 
c 
c c 
c Detector in Box 902 
c c 
c 
521 503 RCC    0    0   0    -18.41 0   0    2.94  $ Al Casing 
522 503 RCC   -0.2  0   0    -18.01 0   0    2.74  $ PMT Vacuum 
529 503 RCC   -0.2  0   0    -0.2   0   0    2.74  $ Foam 0.2cm 
526 503 RCC   -0.4  0   0    -0.05  0   0    2.74  $ Al Window 
527 503 RCC   -0.45 0   0    -5.26  0   0    2.74  $ Al2O3 0.16cm 
525 503 RCC   -0.61 0   0    -5.1   0   0    2.55  $ NaI Crystal  
523 503 RCC   -5.71 0   0    -0.3   0   0    2.74  $ 0.3cm PMT Glass 
c c 
c Detector in Box 903 
c c 
c 
531 504 RCC    0    0   0    -18.41 0   0    2.94  $ Al Casing 
532 504 RCC   -0.2  0   0    -18.01 0   0    2.74  $ PMT Vacuum 
96 
539 504 RCC   -0.2  0   0    -0.2   0   0    2.74  $ Foam 0.2cm 
536 504 RCC   -0.4  0   0    -0.05  0   0    2.74  $ Al Window 
537 504 RCC   -0.45 0   0    -5.26  0   0    2.74  $ Al2O3 0.16cm 
535 504 RCC   -0.61 0   0    -5.1   0   0    2.55  $ NaI Crystal  
533 504 RCC   -5.71 0   0    -0.3   0   0    2.74  $ 0.3cm PMT Glass 
 
C Data Cards 
tr600 -0.1 
tr601 0.1 
tr602 -0.15  
tr603 0.15 
tr604 -0.051 
tr605 0.051 
tr900 0 -0.2 0 0.973527 0.228573 0 -0.228573 0.973527 0 0 0 1 
tr901 0 0.2 0 0.973527 -0.228573 0 0.228573 0.973527 0 0 0 1 
tr903 -0.35 0 0 0.979903 0 -0.199474 0 1 0 0.199474 0 0.979903 
tr501 -10.5 8.75 47.5 0.229 -0.973 0 -0.973 -0.229 0 0 0 1 
tr502 -10.5 -8.75 47.5 0.229 0.973 0 0.973 -0.229 0 0 0 1 
tr503 0 -10.03 78.88 0 1 0 1 0 0 0 0 1 
tr504 17.55 0 -12.5 -0.979903 0 -0.199474 0 1 0 0.199474 0 0.979903 
C VOL   0 9.89817E3 5.12539E4 7.01171E3 4.12839E3 3.75367E4 4.1204E4 & 
C      3.96266E4 3.42787E2 3.43057E2 3.41728E2 3.41505E2 3.3914E2 & 
C      3.38905E2 3.37704E2 3.38854E2 3.36585E2 3.35548E2 3.34261E2 & 
C      3.3525E2 1.09049E4 5.26806E4 5.19336E4 9.87788E3 8.35231E2 & 
C      8.24983E3 1.08532E4 3.48665E3 2.39203E3 5.46974E2 4.19631E2 & 
C      7.21861E2 5.2306E2 1.1077E2 1.11655E2 1.72154E2 3.63227E3 & 
C      5.17342E3 6.31233E3 0 0 8.49751E2 8.55366E2 1.48895E3 1.04544E3 & 
C      3.58882E2 1.45325E2 4.77509E3 8.25008E3 8.23095E3 5.80561E1 &  
C      5.70516E1 2.81453E3 2.80523E3 5.80932E2 5.89508E2 1.56404E2 & 
C      1.56141E2 1.09588E1 1.10836E1 2.31698E2 5.781E2 7.58053E2 & 
C      6.152E2 2.15848E2 1.23531E4 1.09131E4 1.6059E4 1.6059E4 & 
C      1.6059E4 1.6059E4 23.9241 9.2379 53.9171 10.2532 28.10780 & 
C      23.9241 9.2379 53.9171 10.2532 28.1078 23.9241 9.2379 53.9171 & 
C      10.2532 28.1078 23.9241 9.2379 53.9171 10.2532 28.1078 0 
IMP:P 1 98R 0 
C 
C Sources 
SDEF  PAR=2  ERG=D1  CEL=D2  RAD=fcel=D3  & 
      POS=fcel=D4  EXT=fcel=D5  AXS=fcel=D6  
SI1 L 0.662 0.0332 0.0318 
SP1 0.898 0.0392 0.0213 
C Left Lung, Right Lung, Stomach, Small Int., Heart, Ascending Colon,  
C Sigmoid Colon, Transvers Colon, Descending Colon, Bladder,  
C Body Tissue (3, 4, 5, 6, 7, 8, 21, 22, 23, 25) 
SI2 L 2 24 29 40 28 30 31 32 33 45 3 4 5 6 7 8 21 22 23 25 
SP2 D 1 1  1  1  1  1  1  1  1  1  1 1 1 1 1 1 1  1  1  1  
DS3 S 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 
DS4 L 8.5 0 43.4   -8.5 0 43.4   8 -4 35   0 -3.8 11.3   -1 -3 51   & 
      -8.5 -2.36 14.35   5 0 -0.1   -10.6 -2.36 25.5   8.72 0 8.52  & 
      0 -4.5 8   0 0 42.9   0 0 50.8   0 0 42.9   0 0 26.9          & 
      0 0 11.9   0 0 -0.1   0 0 69.9   10.5 0 -80.1   -10.5 0 -80.1 & 
      0 -8 -4.9 
DS5 S 30 31 0 32 0 33 34 35 36 0 37 38 39 40 41 42 43 44 45 46 
DS6 L 0 0 1   0 0 1   0 0 0   0 0 1   0 0 0   0 0 1   0 0 1 & 
      1 0 0   0 0 1   0 0 0   0 0 1   0 0 1   0 0 1   0 0 1 & 
      0 0 1   0 0 1   0 0 1   0 0 1   0 0 1   0 0 1 
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SI7  0 7.6 
SP7  -21 1 
SI8  0 7.6 
SP8  -21 1 
SI9  0 8.2 
SP9  -21 2 
SI10 0 11.4 
SP10 -21 1 
SI11 0 8.2 
SP11 -21 2 
SI12 0 2.6 
SP12 -21 1 
SI13 0 7.1 
SP13 -21 1 
SI14 0 3.85 
SP14 -21 1  
SI15 0 4 
SP15 -21 1  
SI16 0 5.2 
SP16 -21 2 
SI17 0 20.2 
SP17 -21 1 
SI18 0 20.3 
SP18 -21 1 
SI19 0 20.3 
SP19 -21 1 
SI20 0 20.3 
SP20 -21 1 
SI21 0 20.3 
SP21 -21 1 
SI22 0 20.3 
SP22 -21 1 
SI23 0 10.1 
SP23 -21 1 
SI24 0 11 
SP24 -21 1 
SI25 0 11 
SP25 -21 1 
SI26 0 8.1 
SP26 -21 1 
SI27 0 16.6 
SP27 -21 1 
SI30 0 24.6 
SP30 -21 0 
SI31 0 24.6 
SP31 -21 0 
SI32 0 10.2  
SP32 -21 0 
SI33 0 9.75 
SP33 -21 0 
SI34 0 8.92 
SP34 -21 0 
SI35 0 21.2 
SP35 -21 0 
SI36 0 16 
SP36 -21 0 
98 
SI37 0 27.2 
SP37 -21 0 
SI38 0 16.6 
SP38 -21 0 
SI39 0 8.1 
SP39 -21 0 
SI40 0 16.2 
SP40 -21 0 
SI41 0 15.2 
SP41 -21 0 
SI42 0 12.2 
SP42 -21 0 
SI43 0 24.2 
SP43 -21 0 
SI44 0 80.2 
SP44 -21 0 
SI45 0 80.2 
SP45 -21 0 
SI46 0 5 
SP46 -21 0 
C 
C 
C Tally Cards 
c Back Right Lung 
F8:P 501 
E8 0 1e-8 .000876 1020i 3.243776  
FT8 SCX 2  GEB -0.00715076 0.0652825 -0.178934 
c Front Right Lung 
F18:P 511 
E18 0 1e-8 .000876 1020i 3.243776  
FT18 SCX 2 GEB -0.00715076 0.0652825 -0.178934 
c Front Neck Under Chin 
F28:P 521 
E28 0 1e-8 .000876 1020i 3.243776  
FT28 SCX 2 GEB -0.00715076 0.0652825 -0.178934 
c Outer Left Leg 
F38:P 531 
E38 0 1e-8 .000876 1020i 3.243776  
FT38 SCX 2 GEB -0.00715076 0.0652825 -0.178934 
C 
C Material Cards 
C       THIS IS THE COMPOSITION FOR AIR 
M1    7014 -.7558 8016 -.2314 18000 -.0128 
C      THIS IS THE COMPOSITION FOR LUNG TISSUE 
M2    1001 -.1021 
      6012 -.1001 
      7014 -.0280 
      8016 -.7596 
     11023 -.0019 
     15031 -.0008 
     16032 -.0023 
     17000 -.0027 
     19000 -.0020 
     20000 -.0001 
     26000 -.0004 
C        THE COMPOSITION FOR TOTAL BODY MINUS SKELETON AND LUNGS 
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M3    1001 -.1047 
      6012 -.2302 
      7014 -.0234 
      8016 -.6321 
     11023 -.0013 
     12000 -.0002 
     15031 -.0024 
     16032 -.0022 
     17000 -.0014 
     19000 -.0021 
C      THE COMPOSITION FOR SKELETAL TISSUE 
M4    1001 -.0704 
      6012 -.2279 
      8016 -.4856 
      7014 -.0387 
     11023 -.0032 
     12000 -.0011 
     15031 -.0694 
     16032 -.0017 
     17000 -.0014 
     19000 -.0015 
     20000 -.0991 
c      Adult Tissues (Density = 1.04 g/cc) 
M5       1001  -0.10454 
         6012  -0.22663 
         7014  -0.02490 
         8016  -0.63525 
        11023  -0.00112 
        12000  -0.00013 
        14000  -0.00030 
        15031  -0.00134 
        16032  -0.00204 
        17000  -0.00133 
        19000  -0.00208 
        20000  -0.00024 
        26000  -0.00005 
        30000  -0.00003 
        37085  -0.000007217 
        37087  -0.000002783 
        40000  -0.00001 
c Detectors Materials 
C Al Casing 
m501 13027 1 
C Low Density Glass 
m502 14000 0.3333 8000 0.6667 
C Foam 
m503 1000 0.6667 6000 0.3333 
C NaI Crystal 2X2 
m504 11000.04p 0.5 53000.04p 0.5 
C Al2O3 
m509 13027 0.4 8016 0.6 
c STOP NPS 1E8 F38 0.01 
lost 50 
NPS 4E9 
RAND GEN=2 SEED=1561615651 
PHYS:P 4J 1   
100 
PRINT 
MODE P 
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APPENDIX C: COUNT RATE PER 250-mSv INTAKE FOR 
ANTHROPOMORPHIC PHANTOMS 
 102 
Notes on the data: 
 
• Back Right Lung - Posterior Upper Right Torso 
• Front Right Lung - Anterior Upper Right Torso 
• Neck - Anterior Neck 
• Thigh - Lateral left Thigh 
 
 
 
 
CONTENTS OF APPENDIX C 
 
 
Reference Male – Am-241 
Reference Male – Co-60 
Reference Male – Cs-137 
Reference Male – I-131 
Reference Male – Ir-192 
Reference Female – Am-241 
Reference Female – Co-60 
Reference Female – Cs-137 
Reference Female – I-131 
Reference Female – Ir-192 
Adipose Male – Am-241 
Adipose Male – Co-60 
Adipose Male – Cs-137 
Adipose Male – I-131 
Adipose Male – Ir-192 
Adipose Female – Am-241 
Adipose Female – Co-60 
Adipose Female – Cs-137 
Adipose Female – I-131 
Adipose Female – Ir-192 
Post Menopausal Adipose Female – Am-241 
Post Menopausal Adipose Female – Co-60 
Post Menopausal Adipose Female – Cs-137 
Post Menopausal Adipose Female – I-131 
Post Menopausal Adipose Female – I-192 
Child – Am-241 
Child – Co-60 
Child – Cs-137 
Child – I-131 
Child – Ir-192 
 
 103 
Reference Male – Am-241 
 
 
 
Reference Male: Am-241 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Front Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake) 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 7.79E+00 7.44E+00 6.59E-01 2.98E-03 
0.2 5.68E+00 4.49E+00 6.32E-01 1.48E-01 
0.5 5.15E+00 3.86E+00 5.34E-01 1.48E-01 
1.0 4.56E+00 3.13E+00 4.23E-01 1.36E-01 
2.0 4.02E+00 2.43E+00 3.14E-01 9.13E-02 
3.0 3.84E+00 2.18E+00 2.73E-01 6.39E-02 
4.0 3.79E+00 2.07E+00 2.56E-01 5.20E-02 
5.0 3.78E+00 2.02E+00 2.50E-01 4.75E-02 
6.0 3.79E+00 1.99E+00 2.47E-01 4.60E-02 
7.0 3.81E+00 1.97E+00 2.45E-01 4.57E-02 
8.0 3.82E+00 1.95E+00 2.44E-01 4.58E-02 
9.0 3.84E+00 1.93E+00 2.43E-01 4.61E-02 
10.0 3.86E+00 1.92E+00 2.42E-01 4.64E-02 
20.0 4.04E+00 1.77E+00 2.33E-01 4.97E-02 
30.0 4.23E+00 1.66E+00 2.25E-01 5.20E-02 
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Reference Male – Co-60 
 
 
 
Reference Male: 60Co M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Front Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake) 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 2.26E+04 2.15E+04 3.76E+03 7.71E+01 
0.2 2.58E+04 2.64E+04 5.80E+03 2.33E+03 
0.5 2.71E+04 2.76E+04 7.50E+03 3.94E+03 
1.0 2.76E+04 2.78E+04 9.09E+03 5.23E+03 
2.0 2.76E+04 2.74E+04 1.00E+04 5.14E+03 
3.0 2.70E+04 2.67E+04 9.97E+03 4.55E+03 
4.0 2.63E+04 2.61E+04 9.69E+03 4.13E+03 
5.0 2.57E+04 2.54E+04 9.37E+03 3.86E+03 
6.0 2.51E+04 2.48E+04 9.08E+03 3.68E+03 
7.0 2.46E+04 2.43E+04 8.82E+03 3.53E+03 
8.0 2.41E+04 2.38E+04 8.58E+03 3.41E+03 
9.0 2.37E+04 2.33E+04 8.36E+03 3.30E+03 
10.0 2.32E+04 2.29E+04 8.16E+03 3.21E+03 
20.0 2.02E+04 1.99E+04 6.98E+03 2.70E+03 
30.0 1.83E+04 1.81E+04 6.48E+03 2.55E+03 
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Reference Male – Cs-137 
 
 
 
Reference Male: 137Cs F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Front Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake) 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 3.58E+04 3.38E+04 5.05E+03 4.81E+01 
0.2 1.37E+05 1.48E+05 9.42E+04 5.02E+04 
0.5 2.14E+05 2.27E+05 1.56E+05 8.28E+04 
1.0 2.55E+05 2.70E+05 1.89E+05 1.00E+05 
2.0 2.62E+05 2.76E+05 1.94E+05 1.03E+05 
3.0 2.57E+05 2.71E+05 1.90E+05 1.01E+05 
4.0 2.52E+05 2.66E+05 1.87E+05 9.94E+04 
5.0 2.48E+05 2.62E+05 1.84E+05 9.78E+04 
6.0 2.45E+05 2.58E+05 1.82E+05 9.66E+04 
7.0 2.42E+05 2.56E+05 1.80E+05 9.55E+04 
8.0 2.40E+05 2.53E+05 1.78E+05 9.46E+04 
9.0 2.38E+05 2.51E+05 1.76E+05 9.38E+04 
10.0 2.36E+05 2.49E+05 1.75E+05 9.30E+04 
20.0 2.21E+05 2.33E+05 1.64E+05 8.70E+04 
30.0 2.08E+05 2.19E+05 1.54E+05 8.17E+04 
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Reference Male – I-131 
 
 
 
Reference Male: I-131 F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Front Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake) 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 3.58E+04 3.38E+04 4.56E+03 2.21E+01 
0.2 2.24E+04 2.76E+04 5.43E+04 5.50E+03 
0.5 1.04E+04 1.38E+04 6.91E+04 2.44E+03 
1.0 3.85E+03 6.19E+03 7.50E+04 7.36E+02 
2.0 2.24E+03 4.14E+03 7.12E+04 3.90E+02 
3.0 2.43E+03 4.17E+03 6.52E+04 5.11E+02 
4.0 2.64E+03 4.24E+03 5.97E+04 6.23E+02 
5.0 2.78E+03 4.26E+03 5.46E+04 7.06E+02 
6.0 2.85E+03 4.22E+03 4.99E+04 7.63E+02 
7.0 2.88E+03 4.13E+03 4.56E+04 7.99E+02 
8.0 2.86E+03 4.02E+03 4.17E+04 8.17E+02 
9.0 2.81E+03 3.88E+03 3.81E+04 8.22E+02 
10.0 2.74E+03 3.72E+03 3.48E+04 8.16E+02 
20.0 1.62E+03 2.03E+03 1.40E+04 5.22E+02 
30.0 7.65E+02 9.35E+02 5.62E+03 2.53E+02 
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Reference Male – Ir-192 
 
 
 
Reference Male: Ir-192 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Front Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake) 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 1.14E+05 1.08E+05 1.67E+04 9.01E+01 
0.2 1.30E+05 1.30E+05 2.79E+04 1.04E+04 
0.5 1.35E+05 1.36E+05 3.54E+04 1.76E+04 
1.0 1.34E+05 1.33E+05 3.95E+04 2.19E+04 
2.0 1.29E+05 1.27E+05 4.02E+04 1.96E+04 
3.0 1.26E+05 1.24E+05 3.98E+04 1.68E+04 
4.0 1.24E+05 1.21E+05 3.93E+04 1.55E+04 
5.0 1.21E+05 1.19E+05 3.89E+04 1.49E+04 
6.0 1.19E+05 1.17E+05 3.85E+04 1.46E+04 
7.0 1.17E+05 1.15E+05 3.82E+04 1.45E+04 
8.0 1.15E+05 1.13E+05 3.78E+04 1.44E+04 
9.0 1.14E+05 1.12E+05 3.75E+04 1.44E+04 
10.0 1.12E+05 1.10E+05 3.72E+04 1.43E+04 
20.0 9.65E+04 9.55E+04 3.44E+04 1.39E+04 
30.0 8.44E+04 8.39E+04 3.20E+04 1.35E+04 
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Reference Female – Am-241 
 
 
 
Reference Female: Am-241 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 7.42E+00 8.13E-01 4.39E-03 
0.2 5.82E+00 8.14E-01 1.56E-01 
0.5 5.36E+00 6.87E-01 1.59E-01 
1.0 4.87E+00 5.43E-01 1.48E-01 
2.0 4.42E+00 4.02E-01 9.97E-02 
3.0 4.29E+00 3.49E-01 6.89E-02 
4.0 4.26E+00 3.29E-01 5.54E-02 
5.0 4.27E+00 3.20E-01 5.02E-02 
6.0 4.30E+00 3.16E-01 4.85E-02 
7.0 4.32E+00 3.14E-01 4.81E-02 
8.0 4.36E+00 3.13E-01 4.82E-02 
9.0 4.39E+00 3.11E-01 4.85E-02 
10.0 4.42E+00 3.10E-01 4.89E-02 
20.0 4.73E+00 3.01E-01 5.22E-02 
30.0 5.03E+00 2.92E-01 5.46E-02 
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Reference Female – Co-60 
 
 
 
Reference Female: 60Co M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 2.25E+04 4.04E+03 8.85E+01 
0.2 2.48E+04 6.67E+03 2.37E+03 
0.5 2.63E+04 8.83E+03 4.03E+03 
1.0 2.75E+04 1.09E+04 5.28E+03 
2.0 2.79E+04 1.21E+04 5.07E+03 
3.0 2.74E+04 1.20E+04 4.42E+03 
4.0 2.68E+04 1.17E+04 3.98E+03 
5.0 2.62E+04 1.13E+04 3.71E+03 
6.0 2.56E+04 1.09E+04 3.52E+03 
7.0 2.50E+04 1.06E+04 3.38E+03 
8.0 2.45E+04 1.03E+04 3.26E+03 
9.0 2.41E+04 1.00E+04 3.16E+03 
10.0 2.36E+04 9.81E+03 3.07E+03 
20.0 2.05E+04 8.38E+03 2.58E+03 
30.0 1.87E+04 7.79E+03 2.44E+03 
 
 
 
1.00E+02
1.00E+03
1.00E+04
1.00E+05
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
C
o
u
n
ts
 
pe
r 
m
in
u
te
 
pe
r 
25
0-
m
Sv
 
In
ta
ke
Days Following Initial Intake
Back Right Lung
Neck
Thigh
 
 110 
 
Reference Female – Cs-137 
 
 
 
Reference Female: 137Cs F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 3.52E+04 5.49E+03 6.38E+01 
0.2 1.43E+05 1.20E+05 4.89E+04 
0.5 2.24E+05 1.99E+05 8.04E+04 
1.0 2.68E+05 2.41E+05 9.74E+04 
2.0 2.75E+05 2.48E+05 1.00E+05 
3.0 2.69E+05 2.43E+05 9.82E+04 
4.0 2.64E+05 2.38E+05 9.64E+04 
5.0 2.60E+05 2.35E+05 9.49E+04 
6.0 2.57E+05 2.32E+05 9.37E+04 
7.0 2.54E+05 2.29E+05 9.27E+04 
8.0 2.52E+05 2.27E+05 9.18E+04 
9.0 2.50E+05 2.25E+05 9.10E+04 
10.0 2.48E+05 2.24E+05 9.03E+04 
20.0 2.32E+05 2.09E+05 8.44E+04 
30.0 2.18E+05 1.97E+05 7.92E+04 
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Reference Female – I-131 
 
 
 
Reference Female: I-131 F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 3.51E+04 5.05E+03 2.27E+00 
0.2 2.27E+04 5.47E+04 1.80E+02 
0.5 1.12E+04 6.68E+04 8.11E+01 
1.0 4.80E+03 7.14E+04 2.35E+01 
2.0 3.19E+03 6.76E+04 1.00E+01 
3.0 3.32E+03 6.21E+04 1.25E+01 
4.0 3.46E+03 5.69E+04 1.51E+01 
5.0 3.54E+03 5.21E+04 1.71E+01 
6.0 3.56E+03 4.77E+04 1.85E+01 
7.0 3.53E+03 4.37E+04 1.93E+01 
8.0 3.46E+03 4.00E+04 1.97E+01 
9.0 3.37E+03 3.66E+04 1.98E+01 
10.0 3.25E+03 3.35E+04 1.97E+01 
20.0 1.84E+03 1.37E+04 1.26E+01 
30.0 8.56E+02 5.50E+03 6.08E+00 
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Reference Female – Ir-192 
 
 
 
Reference Female: Ir-192 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 1.13E+05 1.85E+04 1.26E+02 
0.2 1.25E+05 3.36E+04 1.04E+04 
0.5 1.31E+05 4.35E+04 1.80E+04 
1.0 1.32E+05 4.90E+04 2.24E+04 
2.0 1.29E+05 5.01E+04 1.97E+04 
3.0 1.27E+05 4.96E+04 1.66E+04 
4.0 1.24E+05 4.91E+04 1.51E+04 
5.0 1.22E+05 4.86E+04 1.45E+04 
6.0 1.20E+05 4.81E+04 1.42E+04 
7.0 1.18E+05 4.77E+04 1.41E+04 
8.0 1.16E+05 4.73E+04 1.40E+04 
9.0 1.14E+05 4.69E+04 1.39E+04 
10.0 1.13E+05 4.66E+04 1.39E+04 
20.0 9.74E+04 4.34E+04 1.35E+04 
30.0 8.53E+04 4.06E+04 1.31E+04 
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Adipose Male – Am-241 
 
 
 
Adipose  Male: Am-241 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 4.09E+00 6.12E-01 1.57E-03 
0.2 3.19E+00 6.52E-01 1.44E-01 
0.5 2.92E+00 5.50E-01 1.46E-01 
1.0 2.62E+00 4.34E-01 1.35E-01 
2.0 2.36E+00 3.20E-01 9.07E-02 
3.0 2.27E+00 2.77E-01 6.27E-02 
4.0 2.25E+00 2.60E-01 5.05E-02 
5.0 2.25E+00 2.54E-01 4.59E-02 
6.0 2.26E+00 2.51E-01 4.43E-02 
7.0 2.28E+00 2.49E-01 4.40E-02 
8.0 2.29E+00 2.48E-01 4.41E-02 
9.0 2.31E+00 2.47E-01 4.44E-02 
10.0 2.32E+00 2.46E-01 4.47E-02 
20.0 2.47E+00 2.40E-01 4.79E-02 
30.0 2.61E+00 2.34E-01 5.02E-02 
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Adipose Male – Co-60 
 
 
 
Adipose  Male: 60Co M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 1.28E+04 3.18E+03 6.62E+01 
0.2 1.46E+04 5.26E+03 2.09E+03 
0.5 1.57E+04 7.11E+03 3.52E+03 
1.0 1.66E+04 8.87E+03 4.67E+03 
2.0 1.69E+04 9.95E+03 4.61E+03 
3.0 1.66E+04 9.91E+03 4.09E+03 
4.0 1.62E+04 9.63E+03 3.73E+03 
5.0 1.58E+04 9.31E+03 3.49E+03 
6.0 1.55E+04 9.01E+03 3.32E+03 
7.0 1.51E+04 8.74E+03 3.19E+03 
8.0 1.48E+04 8.49E+03 3.07E+03 
9.0 1.45E+04 8.27E+03 2.98E+03 
10.0 1.42E+04 8.08E+03 2.89E+03 
20.0 1.23E+04 6.89E+03 2.44E+03 
30.0 1.12E+04 6.41E+03 2.31E+03 
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Adipose Male – Cs-137 
 
 
 
Adipose  Male: 137Cs F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 2.37E+04 4.47E+03 4.68E+01 
0.2 1.12E+05 1.02E+05 9.49E+04 
0.5 1.78E+05 1.70E+05 1.58E+05 
1.0 2.13E+05 2.06E+05 1.92E+05 
2.0 2.19E+05 2.12E+05 1.98E+05 
3.0 2.15E+05 2.08E+05 1.94E+05 
4.0 2.11E+05 2.04E+05 1.90E+05 
5.0 2.07E+05 2.01E+05 1.87E+05 
6.0 2.05E+05 1.98E+05 1.85E+05 
7.0 2.03E+05 1.96E+05 1.83E+05 
8.0 2.01E+05 1.94E+05 1.81E+05 
9.0 1.99E+05 1.92E+05 1.80E+05 
10.0 1.97E+05 1.91E+05 1.78E+05 
20.0 1.85E+05 1.79E+05 1.67E+05 
30.0 1.74E+05 1.68E+05 1.57E+05 
 
 
 
1.00E+02
1.00E+03
1.00E+04
1.00E+05
1.00E+06
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
C
o
u
n
ts
 
pe
r 
m
in
u
te
 
pe
r 
25
0-
m
Sv
 
In
ta
ke
Days Following Initial Intake
Back Right Lung
Neck
Thigh
 
 116 
Adipose Male – I-131 
 
 
 
Adipose  Male: I-131 F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 1.86E+04 3.84E+03 2.22E+01 
0.2 1.35E+04 4.90E+04 4.92E+03 
0.5 6.51E+03 6.11E+04 2.18E+03 
1.0 2.69E+03 6.58E+04 6.58E+02 
2.0 1.75E+03 6.24E+04 3.49E+02 
3.0 1.87E+03 5.73E+04 4.56E+02 
4.0 1.98E+03 5.25E+04 5.57E+02 
5.0 2.05E+03 4.80E+04 6.31E+02 
6.0 2.08E+03 4.40E+04 6.82E+02 
7.0 2.08E+03 4.02E+04 7.14E+02 
8.0 2.05E+03 3.68E+04 7.30E+02 
9.0 2.01E+03 3.37E+04 7.34E+02 
10.0 1.95E+03 3.08E+04 7.29E+02 
20.0 1.12E+03 1.25E+04 4.66E+02 
30.0 5.27E+02 5.02E+03 2.26E+02 
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Adipose Male – Ir-192 
 
 
 
Adipose  Male: Ir-192 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 6.46E+04 1.47E+04 9.18E+01 
0.2 7.32E+04 2.69E+04 9.62E+03 
0.5 7.80E+04 3.53E+04 1.61E+04 
1.0 7.93E+04 4.00E+04 2.00E+04 
2.0 7.76E+04 4.10E+04 1.79E+04 
3.0 7.59E+04 4.06E+04 1.54E+04 
4.0 7.46E+04 4.02E+04 1.42E+04 
5.0 7.33E+04 3.98E+04 1.36E+04 
6.0 7.22E+04 3.95E+04 1.34E+04 
7.0 7.10E+04 3.91E+04 1.33E+04 
8.0 7.00E+04 3.88E+04 1.32E+04 
9.0 6.89E+04 3.85E+04 1.31E+04 
10.0 6.79E+04 3.82E+04 1.31E+04 
20.0 5.91E+04 3.56E+04 1.27E+04 
30.0 5.21E+04 3.34E+04 1.23E+04 
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Adipose Female – Am-241 
 
 
 
Adipose  Female: Am-241 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 5.63E+00 7.52E-01 3.62E-03 
0.2 4.37E+00 7.62E-01 3.54E-01 
0.5 4.00E+00 6.43E-01 3.17E-01 
1.0 3.60E+00 5.08E-01 2.63E-01 
2.0 3.23E+00 3.75E-01 1.80E-01 
3.0 3.12E+00 3.26E-01 1.39E-01 
4.0 3.09E+00 3.06E-01 1.23E-01 
5.0 3.09E+00 2.98E-01 1.17E-01 
6.0 3.11E+00 2.95E-01 1.15E-01 
7.0 3.13E+00 2.93E-01 1.15E-01 
8.0 3.15E+00 2.91E-01 1.16E-01 
9.0 3.17E+00 2.90E-01 1.17E-01 
10.0 3.19E+00 2.89E-01 1.18E-01 
20.0 3.39E+00 2.80E-01 1.27E-01 
30.0 3.59E+00 2.73E-01 1.33E-01 
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Adipose Female – Co-60 
 
 
 
Adipose  Female: 60Co M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 1.56E+04 3.34E+03 6.93E+01 
0.2 1.78E+04 5.57E+03 3.06E+03 
0.5 1.91E+04 7.46E+03 5.43E+03 
1.0 2.02E+04 9.25E+03 7.50E+03 
2.0 2.06E+04 1.03E+04 8.13E+03 
3.0 2.03E+04 1.03E+04 7.70E+03 
4.0 1.98E+04 1.00E+04 7.25E+03 
5.0 1.93E+04 9.67E+03 6.88E+03 
6.0 1.89E+04 9.36E+03 6.59E+03 
7.0 1.85E+04 9.08E+03 6.34E+03 
8.0 1.81E+04 8.82E+03 6.13E+03 
9.0 1.77E+04 8.59E+03 5.94E+03 
10.0 1.74E+04 8.39E+03 5.77E+03 
20.0 1.51E+04 7.16E+03 4.87E+03 
30.0 1.37E+04 6.66E+03 4.61E+03 
 
 
 
1.00E+02
1.00E+03
1.00E+04
1.00E+05
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
C
o
u
n
ts
 
pe
r 
m
in
u
te
 
pe
r 
25
0-
m
Sv
 
In
ta
ke
Days Following Initial Intake
Back Right Lung
Neck
Thigh
 120 
Adipose Female – Cs-137 
 
 
 
Adipose  Female: 137Cs F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 2.37E+04 4.47E+03 4.68E+01 
0.2 1.12E+05 1.02E+05 9.49E+04 
0.5 1.78E+05 1.70E+05 1.58E+05 
1.0 2.13E+05 2.06E+05 1.92E+05 
2.0 2.19E+05 2.12E+05 1.98E+05 
3.0 2.15E+05 2.08E+05 1.94E+05 
4.0 2.11E+05 2.04E+05 1.90E+05 
5.0 2.07E+05 2.01E+05 1.87E+05 
6.0 2.05E+05 1.98E+05 1.85E+05 
7.0 2.03E+05 1.96E+05 1.83E+05 
8.0 2.01E+05 1.94E+05 1.81E+05 
9.0 1.99E+05 1.92E+05 1.80E+05 
10.0 1.97E+05 1.91E+05 1.78E+05 
20.0 1.85E+05 1.79E+05 1.67E+05 
30.0 1.74E+05 1.68E+05 1.57E+05 
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Adipose Female – I-131 
 
 
 
Adipose  Female: I-131 F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 2.35E+04 4.13E+03 2.46E+01 
0.2 1.54E+04 4.58E+04 3.56E+03 
0.5 7.60E+03 5.64E+04 1.59E+03 
1.0 3.29E+03 6.04E+04 4.75E+02 
2.0 2.20E+03 5.72E+04 2.41E+02 
3.0 2.28E+03 5.25E+04 3.13E+02 
4.0 2.37E+03 4.81E+04 3.82E+02 
5.0 2.42E+03 4.41E+04 4.32E+02 
6.0 2.43E+03 4.04E+04 4.67E+02 
7.0 2.40E+03 3.70E+04 4.88E+02 
8.0 2.35E+03 3.38E+04 5.00E+02 
9.0 2.29E+03 3.09E+04 5.02E+02 
10.0 2.21E+03 2.83E+04 4.99E+02 
20.0 1.24E+03 1.15E+04 3.19E+02 
30.0 5.78E+02 4.64E+03 1.54E+02 
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Adipose Female – Ir-192 
 
 
 
Adipose  Female: Ir-192 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 7.99E+04 1.56E+04 1.07E+02 
0.2 9.09E+04 2.89E+04 1.58E+04 
0.5 9.66E+04 3.76E+04 2.67E+04 
1.0 9.82E+04 4.25E+04 3.31E+04 
2.0 9.61E+04 4.35E+04 3.22E+04 
3.0 9.41E+04 4.30E+04 3.00E+04 
4.0 9.24E+04 4.26E+04 2.88E+04 
5.0 9.09E+04 4.22E+04 2.83E+04 
6.0 8.94E+04 4.18E+04 2.80E+04 
7.0 8.80E+04 4.15E+04 2.79E+04 
8.0 8.67E+04 4.11E+04 2.78E+04 
9.0 8.54E+04 4.08E+04 2.77E+04 
10.0 8.41E+04 4.05E+04 2.76E+04 
20.0 7.33E+04 3.77E+04 2.69E+04 
30.0 6.46E+04 3.54E+04 2.61E+04 
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Post Menopausal Adipose Female – Am-241 
 
 
 
Post Menopausal Adipose  Female: Am-241 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 4.69E+00 7.59E-01 2.84E-03 
0.2 3.65E+00 7.70E-01 1.22E-01 
0.5 3.34E+00 6.50E-01 1.23E-01 
1.0 3.00E+00 5.13E-01 1.14E-01 
2.0 2.69E+00 3.80E-01 7.66E-02 
3.0 2.60E+00 3.29E-01 5.31E-02 
4.0 2.57E+00 3.10E-01 4.29E-02 
5.0 2.58E+00 3.02E-01 3.89E-02 
6.0 2.59E+00 2.98E-01 3.76E-02 
7.0 2.60E+00 2.96E-01 3.74E-02 
8.0 2.62E+00 2.95E-01 3.75E-02 
9.0 2.64E+00 2.94E-01 3.77E-02 
10.0 2.66E+00 2.93E-01 3.80E-02 
20.0 2.82E+00 2.84E-01 4.06E-02 
30.0 2.99E+00 2.76E-01 4.25E-02 
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Post Menopausal Adipose Female – Co-60 
 
 
 
Post Menopausal Adipose Female: 60Co M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 1.48E+04 3.75E+03 7.56E+01 
0.2 1.69E+04 6.11E+03 1.84E+03 
0.5 1.81E+04 8.17E+03 3.08E+03 
1.0 1.91E+04 1.01E+04 4.02E+03 
2.0 1.94E+04 1.13E+04 3.87E+03 
3.0 1.91E+04 1.13E+04 3.38E+03 
4.0 1.87E+04 1.09E+04 3.06E+03 
5.0 1.82E+04 1.06E+04 2.85E+03 
6.0 1.78E+04 1.02E+04 2.71E+03 
7.0 1.74E+04 9.94E+03 2.60E+03 
8.0 1.70E+04 9.66E+03 2.51E+03 
9.0 1.67E+04 9.42E+03 2.43E+03 
10.0 1.64E+04 9.19E+03 2.36E+03 
20.0 1.42E+04 7.85E+03 1.99E+03 
30.0 1.29E+04 7.30E+03 1.88E+03 
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Post Menopausal Adipose Female – Cs-137 
 
 
 
Post Menopausal Adipose  Female: 137Cs F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 4.48E+03 1.39E+03 4.86E+01 
0.2 2.27E+04 2.10E+04 8.75E+03 
0.5 3.60E+04 3.46E+04 1.41E+04 
1.0 4.31E+04 4.20E+04 1.70E+04 
2.0 4.42E+04 4.32E+04 1.74E+04 
3.0 4.33E+04 4.23E+04 1.71E+04 
4.0 4.25E+04 4.15E+04 1.68E+04 
5.0 4.18E+04 4.09E+04 1.65E+04 
6.0 4.13E+04 4.04E+04 1.63E+04 
7.0 4.08E+04 3.99E+04 1.61E+04 
8.0 4.04E+04 3.95E+04 1.59E+04 
9.0 4.01E+04 3.92E+04 1.58E+04 
10.0 3.98E+04 3.89E+04 1.57E+04 
20.0 3.72E+04 3.64E+04 1.46E+04 
30.0 3.49E+04 3.41E+04 1.37E+04 
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Post Menopausal Adipose Female – I-131 
 
 
 
Post Menopausal Adipose  Female: I-131 F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 2.16E+04 4.63E+03 2.69E+01 
0.2 1.57E+04 5.18E+04 4.13E+03 
0.5 7.71E+03 6.37E+04 1.83E+03 
1.0 3.31E+03 6.82E+04 5.52E+02 
2.0 2.22E+03 6.46E+04 2.87E+02 
3.0 2.33E+03 5.94E+04 3.74E+02 
4.0 2.45E+03 5.44E+04 4.56E+02 
5.0 2.51E+03 4.98E+04 5.16E+02 
6.0 2.53E+03 4.56E+04 5.57E+02 
7.0 2.52E+03 4.18E+04 5.83E+02 
8.0 2.48E+03 3.82E+04 5.96E+02 
9.0 2.41E+03 3.50E+04 6.00E+02 
10.0 2.33E+03 3.20E+04 5.95E+02 
20.0 1.33E+03 1.30E+04 3.81E+02 
30.0 6.19E+02 5.24E+03 1.84E+02 
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Post Menopausal Adipose Female – I-192 
 
 
 
Post Menopausal Adipose Female: Ir-192 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 7.43E+04 1.74E+04 1.21E+02 
0.2 8.48E+04 3.14E+04 8.14E+03 
0.5 8.98E+04 4.07E+04 1.38E+04 
1.0 9.11E+04 4.60E+04 1.71E+04 
2.0 8.90E+04 4.70E+04 1.50E+04 
3.0 8.71E+04 4.66E+04 1.27E+04 
4.0 8.56E+04 4.61E+04 1.16E+04 
5.0 8.41E+04 4.57E+04 1.11E+04 
6.0 8.28E+04 4.52E+04 1.09E+04 
7.0 8.15E+04 4.48E+04 1.08E+04 
8.0 8.02E+04 4.45E+04 1.07E+04 
9.0 7.90E+04 4.41E+04 1.07E+04 
10.0 7.79E+04 4.38E+04 1.06E+04 
20.0 6.77E+04 4.08E+04 1.03E+04 
30.0 5.97E+04 3.81E+04 1.00E+04 
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Child – Am-241 
 
 
 
Child: Am-241 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 1.25E+01 1.98E+00 1.28E-02 
0.2 8.86E+00 1.74E+00 2.90E-01 
0.5 7.91E+00 1.48E+00 3.29E-01 
1.0 6.88E+00 1.18E+00 3.02E-01 
2.0 5.89E+00 8.79E-01 1.84E-01 
3.0 5.54E+00 7.64E-01 1.12E-01 
4.0 5.42E+00 7.19E-01 8.05E-02 
5.0 5.38E+00 7.00E-01 6.83E-02 
6.0 5.37E+00 6.90E-01 6.39E-02 
7.0 5.38E+00 6.85E-01 6.25E-02 
8.0 5.39E+00 6.80E-01 6.23E-02 
9.0 5.40E+00 6.77E-01 6.25E-02 
10.0 5.42E+00 6.74E-01 6.29E-02 
20.0 5.56E+00 6.44E-01 6.65E-02 
30.0 5.72E+00 6.19E-01 6.91E-02 
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Child – Co-60 
 
 
 
Child: 60Co M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 3.04E+04 6.59E+03 2.90E+02 
0.2 3.59E+04 1.09E+04 4.17E+03 
0.5 3.88E+04 1.40E+04 6.43E+03 
1.0 4.11E+04 1.69E+04 7.95E+03 
2.0 4.20E+04 1.86E+04 6.98E+03 
3.0 4.13E+04 1.85E+04 5.68E+03 
4.0 4.03E+04 1.79E+04 4.93E+03 
5.0 3.93E+04 1.74E+04 4.51E+03 
6.0 3.83E+04 1.68E+04 4.25E+03 
7.0 3.75E+04 1.63E+04 4.07E+03 
8.0 3.67E+04 1.59E+04 3.92E+03 
9.0 3.59E+04 1.55E+04 3.80E+03 
10.0 3.53E+04 1.51E+04 3.70E+03 
20.0 3.06E+04 1.29E+04 3.12E+03 
30.0 2.80E+04 1.20E+04 2.93E+03 
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Child – Cs-137 
 
 
 
Child: 137Cs F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 1.10E+05 2.22E+04 5.81E+02 
0.2 5.66E+05 4.01E+05 1.29E+05 
0.5 8.75E+05 6.48E+05 2.07E+05 
1.0 1.03E+06 7.75E+05 2.48E+05 
2.0 1.06E+06 7.96E+05 2.55E+05 
3.0 1.04E+06 7.82E+05 2.50E+05 
4.0 1.02E+06 7.68E+05 2.45E+05 
5.0 1.01E+06 7.58E+05 2.42E+05 
6.0 9.95E+05 7.49E+05 2.38E+05 
7.0 9.85E+05 7.41E+05 2.36E+05 
8.0 9.77E+05 7.34E+05 2.34E+05 
9.0 9.69E+05 7.29E+05 2.32E+05 
10.0 9.62E+05 7.23E+05 2.30E+05 
20.0 9.06E+05 6.79E+05 2.15E+05 
30.0 8.55E+05 6.40E+05 2.02E+05 
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Child – I-131 
 
 
 
Child: I-131 F 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 1.87E+04 3.60E+03 6.23E+01 
0.2 1.54E+04 1.66E+04 3.09E+03 
0.5 7.87E+03 1.65E+04 1.39E+03 
1.0 3.70E+03 1.60E+04 4.03E+02 
2.0 2.64E+03 1.49E+04 1.74E+02 
3.0 2.71E+03 1.38E+04 2.18E+02 
4.0 2.78E+03 1.28E+04 2.64E+02 
5.0 2.81E+03 1.18E+04 2.99E+02 
6.0 2.80E+03 1.10E+04 3.22E+02 
7.0 2.76E+03 1.01E+04 3.37E+02 
8.0 2.69E+03 9.35E+03 3.44E+02 
9.0 2.61E+03 8.62E+03 3.46E+02 
10.0 2.51E+03 7.95E+03 3.43E+02 
20.0 1.39E+03 3.41E+03 2.19E+02 
30.0 6.43E+02 1.41E+03 1.06E+02 
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Child – Ir-192 
 
 
 
Child: Ir-192 M 
Days Back Right Lung 
(cpm per 250-
mSv Intake) 
Neck 
(cpm per 250-
mSv Intake 
Thigh 
(cpm per 250-
mSv Intake) 
0.0 1.10E+05 2.30E+04 4.20E+02 
0.2 1.30E+05 3.95E+04 1.23E+04 
0.5 1.39E+05 4.97E+04 2.01E+04 
1.0 1.41E+05 5.51E+04 2.43E+04 
2.0 1.38E+05 5.58E+04 1.96E+04 
3.0 1.35E+05 5.50E+04 1.51E+04 
4.0 1.32E+05 5.44E+04 1.29E+04 
5.0 1.30E+05 5.38E+04 1.20E+04 
6.0 1.28E+05 5.32E+04 1.17E+04 
7.0 1.26E+05 5.27E+04 1.15E+04 
8.0 1.24E+05 5.23E+04 1.14E+04 
9.0 1.22E+05 5.18E+04 1.13E+04 
10.0 1.21E+05 5.14E+04 1.13E+04 
20.0 1.06E+05 4.76E+04 1.09E+04 
30.0 9.35E+04 4.43E+04 1.05E+04 
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APPENDIX D: SAMPLE TRIAGE PROCEDURE SHEET FOR FIRST 
RESPONDERS
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